   IRB#:11- 183 A  (2) 
1 
Amended: 20 -JAN -2016 
  
 
 
Pediatric Oncology Experimental Therapeutic s Investigator s’ Consortium (POETIC)  
 
A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients 
with Relapsed/Refractory Ewing’s Sarcoma and Neuroblastoma  
 
Study Drug  
Bevacizumab (Avastin®)  
 
Support Provided By  
[CONTACT_8229], Inc.  
 
Sponsor Investigator  
Tanya Trippett, M.D.  
Lia Gor e, M.D.  
 
Sub-Investigators  
David Lyden, M.D., Ph.D.  
 
Aru Narendran, M.D., Ph.D.  
 
Research Nurse  
Geraldine Wright, RN  
 
Statistician  
     Irina Ostrovnaya, Ph. D. 
 
 
 
 
 
Study Number  POE10 -01 
 
Protocol History  
Version 1.0   11/30/2011  
Version 2.0   01/30/2013  
Version 3.0   01/05/2016   
 
 
 
  
 
 
   IRB#:11- 183 A  (2) 
2 
Amended: 20 -JAN -2016 
 Principal 
Investigator:  
 
[INVESTIGATOR_200900], MD  
POETIC Data and Coordinating Center  
Memorial Sloan- Kettering Cancer Center  
[ADDRESS_239533]  
[LOCATION_001], NY  [ZIP_CODE]  
Telephone     (212) 639- 8267  
Fax                (212) 717- 3239 
E-mail            [EMAIL_3936]   Data Managers:  
 
Stephanie Limones  
POETIC Data and Coordinating Center  
Memorial Sloan- Kettering Cancer Center  
[ADDRESS_239534], Room 3- 516 
[LOCATION_001], NY [ZIP_CODE]   
Telephone         (646) 888- 5714  
Fax                    (646) 888- 5726  
E-mail                limoness @mskcc.org   
 
 
Co-Principal 
Investigators:  Lia Gore, MD  
University of Colorado Health Sciences Center  and 
The Children’s Hospi[INVESTIGATOR_200901] B115  
[ADDRESS_239535] 
Aurora, CO  [ZIP_CODE]  
Telephone   ([PHONE_4315]  
Fax              ([PHONE_4316]  
E-mail          [EMAIL_3937]   
 Debra Schissel, RN  
University of Colorado Health Sciences Center  
and The Children’s Hospi[INVESTIGATOR_200901] B115  
[ADDRESS_239536] 
Aurora, CO  [ZIP_CODE]  
Telephone   ([PHONE_4315]  
Fax              ([PHONE_4316]  
Email           [EMAIL_3938]  
Investigator (s):   
 Jessica Boklan, MD  
Phoenix Children’s Hospi[INVESTIGATOR_200902]  
[ADDRESS_239537] / Outpatient Bldg B  
Phoenix, AZ  [ZIP_CODE]- 7710  
Telephone    (602) 546- 0920  
Fax               (602) 546- 0276  
E-mail           [EMAIL_3939]   Sam Chimienti  
Phoenix Children’s Hospi[INVESTIGATOR_200903] & Blood Disorders  
[ADDRESS_239538] / Outpatient Bldg B  
 Phoenix, AZ  [ZIP_CODE]- 7710  
 Telephone    (602) 546- 5004 
 Fax               (602) 546- 0211  
 E-mail           [EMAIL_3940]  
 
 
  
 
 
 
 
 
 
  
 
 
 
 
  
   IRB#:11- 183 A  (2) 
3 
Amended: 20 -JAN -2016 
  
 
 Tony Truong, MD  
Alberta Children's Hospi[INVESTIGATOR_307]  
2888 Shaganappi [INVESTIGATOR_200904], Alberta  T3B 6A8  
Telephone     ( [PHONE_4317]  
Fax                ( [PHONE_4318] 
E-mail        [EMAIL_3941]  Karen Mazil, RN  
Alberta Children's Hospi[INVESTIGATOR_307]  
2888 Shaganappi [INVESTIGATOR_200904], Alberta  T3B 6A8  
Telephone     ( [PHONE_4319]  
Fax                ( [PHONE_4320] 
E-mail            [EMAIL_3942]  
 
 Keith August , MD  
Children’s Mercy Hospi[INVESTIGATOR_84059]  
[ADDRESS_239539].  
Kansas City, MO, [ZIP_CODE]  
Telephone     ( 816) 234- 3059  
Fax                ( 816) [ADDRESS_239540] @cmh.edu  Amber Jenkins  MSc, CCRC  
Children’s Mercy Hospi[INVESTIGATOR_84059]  
[ADDRESS_239541].  
Kansas City, MO, [ZIP_CODE]  
Telephone     ( [PHONE_4321]  
Fax                ( [PHONE_4322] 
E-mail            [EMAIL_3943]  
 
 Lisa M. McGregor , MD , PhD  
Pennsylvania State University College of Medicine  
[ADDRESS_239542]; MC H085  
  Hershey, PA  [ZIP_CODE]- 0850  
Telephone     ( [PHONE_4323]  
Fax                ( [PHONE_4324] 
  E-mail            [EMAIL_3944]  
 Kathryn By[CONTACT_18050], BS, CCRP  
Pennsylvania State University College of  Medicine  
[ADDRESS_239543]; H085, Room C7830  
  Hershey, PA  [ZIP_CODE]- 0850  
Telephone     ( [PHONE_4325]  
Fax                ( 717) 531- 0120 
  E-mail            [EMAIL_3945]  
 
   
   
 
 
 
  
 
 
 
 
 
 
 
 
   IRB#:11- 183 A  (2) 
4 
Amended: 20 -JAN -2016 
 TABLE OF CONTENTS  
                                                                         Page #  
1.0 BACKGROUND……………………………………………………………………….......  8 
1.1 Disease Background  ........................................................................................  8 
1.1.1  Rationale for Targeting VEGF in Pediatric Malignancies  ...................  8 
1.2 Bevacizumab Clinical Experience ....................................................................  9 
1.2.1  Safety Profile  .....................................................................................  10 
1.3 Other Study Drug(s) Background  .....................................................................  18  
1.4 Study Rationale ...............................................................................................  19 
1.5 Rationale for Correlative Studies .....................................................................  20 
1.5.1  Rationale for Investigating EPCs/HPCs  .............................................  [ADDRESS_239544] of bevacizumab on growth and development in children..  23 
2.0 OBJECTIVES ........................................................................................................  23 
2.1  Primary  ...................................................................................................  23 
2.2  Secondary  ...............................................................................................  23 
2.3  Exploratory  ..............................................................................................  24 
3.0 STUDY DESIGN  ....................................................................................................  24 
3.1 Description of the Study  .............................................................................  24 
3.2 Rationale for Study Design .........................................................................  24 
3.3 Outcome Measures  ....................................................................................  25 
3.3.1  Primary Outcome Measures  ..............................................................  25 
3.3.2  Secondary Outcome Measures  .........................................................  25 
3.3.3  Safety Outcome Measures  ................................................................  25 
4.0 SAFETY PLAN  ......................................................................................................  25 
4.1 General Plan to Manage Safety ……………………………………………… .. [ADDRESS_239545] Selection  .......................................................................................  27 
5.2 Inclusion Criteria  ........................................................................................  27 
5.3 Exclusion Criteria  .......................................................................................  28 
6.0 STUDY DESIGN …………………………………………………………………………  30 
6.1 Treatment Plan ..........................................................................................  31 
6.2  Number of Centers  .....................................................................................  31 
   IRB#:11- 183 A  (2) 
5 
Amended: 20 -JAN -2016 
 6.3  Number of Subjects ....................................................................................  31 
6.4  Estimated Study Duration...........................................................................  32 
7.0 STUDY MEDICATION ...........................................................................................  32 
7.1 Bevacizumab Dosage and Formulation  .....................................................  32 
7.1.1  Bevacizumab Administration ........................................................  32 
7.1.2  Bevacizumab Storage  ..................................................................  32 
7.1.3  Bevacizumab Dose Modification and Toxicity Management .........  33 
7.1.4  Investigational Agent Management ……………………………….... . 36  
7.1.5  Drug Accountability  ......................................................................  37 
7.1.6 Disposition of Used Supplies  .......................................................  38 
7.1.7 Inventory of Unused Supplies  ......................................................  38 
7.2 Protocol -Specified Chemotherapy  ..............................................................  39 
7.2.1  Cyclophosphamide (Cytoxan) NSC #[ZIP_CODE]……………………… .  39 
[IP_ADDRESS]   Source and Pharmacology ……………………………………   39 
[IP_ADDRESS]     Formulation…………………………………………………  ......  39 
[IP_ADDRESS]     Storage ……………………………………………………… .....  39 
[IP_ADDRESS]      Reconstitution………………………………………………  ......  40 
[IP_ADDRESS]      Stability …………………………………………………………  .  40 
[IP_ADDRESS]      Admi nistration…… …………………………………………  ......  40 
7.2.1. 7      Supplier …………………………………………………………  .  40 
7.2.1. 8      Safety profile … ...................................................................  40 
 7.2.2          Topotecan, NSC #609699, IND #[ZIP_CODE]………  ............................  41 
[IP_ADDRESS]          Source and Pharmacology   ..............................................   41 
[IP_ADDRESS]          Formulation ......................................................................  41 
[IP_ADDRESS]          Storage ............................................................................  41 
[IP_ADDRESS]          Reconstitution ..................................................................  41 
[IP_ADDRESS]          Stability  ............................................................................   41 
[IP_ADDRESS]          Administration ..................................................................  42 
[IP_ADDRESS]          Supplier  ...........................................................................  42 
[IP_ADDRESS]          Safety profile  ....................................................................  42 
7.3 Concomitant Medications  ...........................................................................  43 
7.3.1 Prior Treatmen t ....................................................................................   43 
7.3.2 Permitted  Treatment  ............................................................................  43 
8.0 CLINICAL AND LABORAT ORY EVALUATIONS  ...................................................  44 
   IRB#:11- 183 A  (2) 
6 
Amended: [ADDRESS_239546]-Treatment Evaluations  .......................................................................  46 
8.4 Study Termination Visit  ..............................................................................  46 
8.5 Overall Survival and Time To Progression  .................................................  46 
8.6 Criteria For Therapeutic Response/Outcome Assessment  .........................  49 
8.6.1  Definition of Response in Patients  .....................................................  49 
[IP_ADDRESS]  Measureable Disease  ..................................................................  49 
[IP_ADDRESS]  Non-Measureable Disease ..........................................................  49 
[IP_ADDRESS]  Target Lesions  .............................................................................  50 
[IP_ADDRESS]  Non-Target Lesions  .....................................................................  50 
[IP_ADDRESS]  Guidelines for Evaluation of Measurable Disease ........................  50 
8.6.2  Response Criteria  ..............................................................................  51 
[IP_ADDRESS]       Evaluation of Target Lesions  .................................................  51 
[IP_ADDRESS]       Evaluation of Non- Target Lesions  ..........................................  [ADDRESS_239547] Overall Response  .............................................  52 
8.6.4       Confirmatory Measurement/Duration of Response .........................  52 
[IP_ADDRESS] Confirmation  ................................................................................  52 
[IP_ADDRESS] Duration of Response ..................................................................  52 
[IP_ADDRESS] Duration of Stable Disease ..........................................................  [ADDRESS_239548] DISCONTINUAT ION ............................................................................  57 
10.0 STUDY DISCONTINUATIO N ................................................................................  58 
11.0 STATISTICAL METHODS .....................................................................................  58 
11.1 Determination of Sample Size  .......................................................................  58 
11.2 Stratification of Accrual ……………  ................................................................  58 
11.3 Planned Efficacy Evaluations  ........................................................................  58 
11.3.1 Primary Efficacy Variables  ..............................................................  58 
   IRB#:11- 183 A  (2) 
7 
Amended: 20 -JAN -2016 
 11.3.2 Secondary Efficacy Variables  .........................................................  59 
11.3.3 Methods of Analysis  .......................................................................  59 
11.4  Analysis of Correlative Studies ......................................................................  59 
12.0 SAFETY REPORTING OF ADVERSE EVENTS …. ...............................................  60 
12.1 Adverse Events Reporting and Definitions  ....................................................  60 
12.2 Reporting of Serious Treatment Emergent Adverse Events  ..........................  61 
12.2.1 Reporting of STEAE to Sponsor  .........................................................  63 
12.3 Safety Reporting Requirements for IND Holders  ...........................................  64 
12.4 Safety Reporting Requirements for IND Exempt Studies  ...............................  66 
13.0     RETENTION OF RECORDS  ..............................................................................  66 
14.0     RECRUITEMENT PLAN/INFORMED CONSENT PROCEDURES  .....................  66 
15.0 RESEARCH PARTICIPANT REGISTRATION AND RANDOMIZATION        
PROCEDURES  ..................................................................................................  68 
15.1 Research Participant Registration  .................................................................   69 
15.2  Randomization  ..............................................................................................  69 
16.0   DATA MANAGEMENT ISSUES ...........................................................................  69 
16.1 Data and Coordinating Center  .......................................................................  69 
16.2 Site Research Staff  ........................................................................................  70 
16.3 Administrative Support  ...................................................................................  71 
16.4 Additional IRB Correspondence .....................................................................  72 
16.5 Quality Assurance  ..........................................................................................   72 
16.6 Data and Safety Monitoring ...........................................................................  73 
16.7 Therapeutic Response Review  ......................................................................  74 
17.0   PROTECTION OF HUMAN SUBJECTS  ...............................................................  74 
17.1 Privacy  ...........................................................................................................  74 
 
 
REFERENCES  
 APPENDICES    (Separate Documents)   
 
Appendix A:  Study Flowchart  
Appendix B:  Informed Consent  
Appendix C:  NCI Common Toxicity Criteria  
Appendix D:  FDA MedWatch 3500a Form  
Appendix E: NYHA Guidelines  
Appendix F:  Procedure for Obtaining a Urine Protein / Creatinine Ratio  
   IRB#:11- 183 A  (2) 
8 
Amended: 20 -JAN -2016 
 Appendix G:  Blood Pressure Normal Values in Children 
Appendix H:  Serum Creatinine Normal Values in Children 
Appendix I:      Procedural Manual  
 
1.[ADDRESS_239549] the 
tumor -associated growth factors and chemokines, vascular endothelial growth factor 
(VEGF) family members represent a prominent group of proangiogenic factors secreted 
by [CONTACT_200940], leukemias and lymphomas.2,[ADDRESS_239550] identified this molecule as the vascular permeability factor (VPF), which 
resulted in the leakage of plasma proteins, growth factors, and platelets from the 
circulation to the tissue parenchyma in tumors and in distant org ans.4,5 For a second 
mechanism of action, VEGF specific receptors were found on the surface of mature 
endothelial cells promoting the growth of new blood vessels. Folkman et al  
demonstrated that endothelial cell proliferation at the tips of established blood vessels 
formed branching of new blood vessels to the tumor site enabling the continued growth 
of the primary tumor.6 One member of this family , VEGF -A, was shown to  promote  new 
blood vessel formation by [CONTACT_200941] 2 (VEGFR2) on endothelial 
cells.[ADDRESS_239551]  
shown that VEGF- A signals through two tyrosine kinase receptors, VEGFR1 and 
VEGFR2, expressed on bone marrow -derived stem and progenitor cells. Endothelial 
progenitor cells (EPCs) expressing VEGFR2 and hematopoietic progenitor cells (HPCs) 
expressing VEGFR1 were both required to form the earliest blood vessels 
(neovasculogenesis) in  tumors. During early tumorigenesis, VEGF -A specifically 
promoted the proliferation and recruitment of VEGFR2+ EPCs to the primary tumor site. 
Similarly, VEGF -A promoted the production and mobilization of VEGFR1+ HPCs to the 
tumor as well. Although less we ll studied, VEGFR1+ HPCs appear to play a critical role 
in regulating the interactions, such as adhesive properties, between tumor cells, endothelial cells along with the adjoining inflammatory infiltrates. VEGFR1
+ HPCs may 
also contribute to the perivascular cell network for the stabilization of blood vessel s.  As 
a third mechanism, VEGF can mobilize VEGFR1+ HPCs to future sites of metastasis 
forming the “pre -metastatic niche” or the preconditioning necessary for a favorable 
microenvironment suitable for t he arrival of incoming metastatic tumor cells8. In addition 
to VEGF -A, other VEGF family members, VEGF -B and PlGF (placental growth factor), 
can support the mobilization of VEGFR1+ HPCs to the primary tumor and to the pre-
metastatic sites.  
Besides its paracrine effects and as a fourth mechanism, VEGF -A and its receptors,  
VEGFR1 and VEGFR2, form an autocrine loop on certain tumor cells enabling the direct 
support of certain tumor cell growth. VEGF- A and its receptors are expressed in 
leukemia and lymphoma as well as pediatric sarcomas and neuroblastomas 9,10. Given 
the potential autocrine and paracrine effects of VEGF- A, it is not surprising that higher 
VEGF levels have been associated with worse prognosis in pediatric and adult patients 
with both liquid and  solid tumors 11, 12, 13.   
 
   IRB#:11- 183 A  (2) 
9 
Amended: [ADDRESS_239552] a better cure rate than the majority of adult  cancers. 
However, refractory disease and the potential for long -term morbidity from the use of 
conventional therapi[INVESTIGATOR_200905].  
The promise of anti -angiogenic therapy includes reduced toxicity and the potential for 
efficacy predominantly by [CONTACT_52330]’s blood supply.  Novel agents such as 
bevacizumab are easily administered with little or no significant toxicity. In fact, no MTD 
was established in the Phase I COG study of bevacizumab in refracto ry pediatric solid 
tumors.  Treatment was well tolerated with no DLTs observed. Adverse events including 
infusional reaction, rash, mucositis, proteinuria, and lymphopenia were Grade 1-  [ADDRESS_239553] cytotoxic chemotherapeutic agents .  
 
1.2 Bevacizumab Clinical Experience     
Bevacizumab has been studied in a multitude of Phase I, II, and III clinical trials in more 
than 5000 patients and in multiple tumor types. In addition, data are available from 3,863 
patients enrolled in two postmarketing studies in metastatic colorectal cancer (CRC).  
Approximately 130,[ADDRESS_239554] or in clinical trials.  The following discussion summarizes bevacizumab’s safety 
profile and presents some of the efficacy results pertinent to this particular trial. Please 
refer to the bevacizumab Investigator Brochure for descriptions of all completed Phase I, 
II, and III trials reported to date.  
 In a large phase III study (AVF2107g) in patients with metastatic colorectal cancer, the 
addition of bevacizumab, a monoclonal antibody directed against vasc ular endothelial 
growth factor (VEGF), to irinotecan/5 -fluorouracil/leucovorin (IFL) chemotherapy resulted 
in a clinically and statistically significant increase in duration of survival, with a hazard 
ratio of death of 0.67 (median survival 15.6 vs. 20.3 months; p < 0.001).  Similar 
increases were seen in progression- free survival (6.2 vs. 10.6 months; p < 0.001), 
overall response rate (35% vs. 45%; p < 0.01) and duration of response (7.1 vs. 10.4 
months; p  < 0.01) for the combination arm versus the chemotherapy only arm 
(bevacizumab Investigator Brochure, October 2005).  
 
Based on the survival advantage demonstrated in Study AVF2107g, bevacizumab was 
designated for priority review and was approved on [ADDRESS_239555]- line treat ment in combination with IV 5- FU−based chemotherapy for 
subjects with metastatic colorectal cancer.  
 
Additional data from Phase III trials in metastatic CRC (E3200), non −small cell lung 
cancer (NSCLC; E4599), and metastatic breast cancer (E2100) have also demonstrated 
clinical benefit from bevacizumab when added to chemotherapy.  In Study E3200, the 
   IRB#:11- 183 A  (2) 
10 
Amended: 20 -JAN -2016 
 addition of bevacizumab to FOLFOX chemotherapy resulted in improved overall survival 
compared with FOLFOX alone (13.0 vs. 10.8 months, respectively, HR  = 0.75;  p < 0.01) 
in a population of previously treated CRC patients.   
 
There was also improved overall survival in first -line NSCLC patients (E4599) treated 
with carboplatin/paclitaxel  + bevacizumab compared with chemotherapy alone (12.3 vs. 
10.3 months, respectively; HR  = 0.80; p  = 0.003).  The results from this trial were the 
basis for FDA approval of bevacizumab for use in combination with 
carboplatin + paclitaxel as first -line treatment of patients with unresectable, locally 
advanced, recurrent or metastatic, non- squamous NSCLC in October 2006.  Finally, 
patients with untreated metastatic breast cancer (E2100) who received bevacizumab in 
combination with weekly paclitaxel had a marked improvement in PFS compared with 
chemotherapy alone (13.3 vs. 6.7 months, respectively; HR  = 0.48; p < 0.0001) (see the 
Bevacizumab Investigator Brochure for additional details).  
 
1.2.1 . Safety Profile  
In the initial Phase I and II clinical trials, four potential bevacizumab- associated safety 
signals were identified: hypert ension, proteinuria, thromboembolic events, and 
hemorrhage.  Additional completed Phase II and Phase III studies of bevacizumab as 
well as spontaneous reports have further defined the safety profile of this agent. 
Bevacizumab- associated adverse events identified in phase III trials include congestive 
heart failure (CHF) primarily in metastatic breast cancer, gastrointestinal perforations, 
wound healing complications, and arterial thromboembolic events (ATE). These and 
other safety signals are described in f urther detail as follows and in the bevacizumab 
Investigator Brochure.  
 
Hypertension: An increased incidence of hypertension has been observed in patients 
treated with bevacizumab.  Grade [ADDRESS_239556] included hypertensive crisis, hypertensive 
encephalopathy, and reversible posterior leukoencephalopathy syndrome (RPLS) 
(Ozcan et al., 2006; Glusker et al., 2006).  
 
There is no information on the effect of bevacizumab in patients with uncontrolled 
hypertension at the time of initiating bevacizumab therapy.  Therefor e, caution should be 
exercised before initiating bevacizumab therapy in these patients.  Monitoring of blood 
pressure is recommended during bevacizumab therapy.  Optimal co ntrol of blood 
pressure according to standard public health guidelines is recommended for patients on treatment with or without bevacizumab.   
 
Temporary interruption of bevacizumab therapy is recommended in patients with 
hypertension requiring medical therapy until adequate control is achieved.  
If hypertension cannot be controlled with medical therapy, bevacizumab therapy should 
be permanently discontinued.  Bevacizumab should be permanently discontinued in patients who develop hypertensive crisis or hypertensive encephalopathy.  
 Reproductive System And Breast Disorders : Loss of the norm al functioning of the 
ovaries in a woman that can result in temporary or permanent menopause; the impact 
on fertility (temporary or permanent) is unknown.  
 
   IRB#:11- 183 A  (2) 
11 
Amended: 20 -JAN -2016 
  Ovarian failure, defined as amenorrhea lasting 3 or more months with follicle- stimulating 
hormone (FSH) elevation (≥30 mIU/mL), was increased in patients receiving adjuvant 
bevacizumab plus mFOLFOX compared to mFOLFOX alone (34% vs. 2%).   After 
discontinuation of bevacizumab, resumption of menses and an FSH level <30 mIU/mL 
was demonstrated in 22% (7/32) of these women.   Long term effects of bevacizumab 
exposure on fertility are unknown.  However, this risk is only applicable to female, 
premenopausal patients.  
 
Proteinuria :  An increased incidence of proteinuria has been observed in patients 
treated wit h bevacizumab compared with control arm patients.  In the 
bevacizumab- containing treatment arms of clinical trials (across all indications), the 
incidence of proteinuria (reported as an adverse event) was up to 38% (metastatic CRC 
Study  AVF2192g).  The severity of proteinuria has ranged from asymptomatic and 
transient events detected on routine dipstick urinalysis to nephrotic syndrome; the majority of proteinuria events have been grade 1. NCI -CTC Grade 3 proteinuria was 
reported in up to 3% of bevacizumab- treated patients, and Grade  4 in up to 1.4% of 
bevacizumab- treated patients.  The proteinuria seen in bevacizumab clinical trials was 
not associated with renal impairment and rarely required permanent discontinuation of 
bevacizumab therapy.  Bevacizumab should be discontinued in patients who develop 
Grade 4 proteinuria (nephrotic syndrome) . 
 
Patients with a history of hypertension may be at increased risk for the development of 
proteinuria when treated with bevacizumab.  There is evidence from the dose- finding, 
Phase II trials (AVF0780g, AVF0809s, and AVF0757g) suggesting that Grade 1 
proteinuria may be related to bevacizumab dose.  
 Proteinuria will be monitored by [CONTACT_39701]:creatinine (UPC) ratio at least every 6 
weeks.  If the UPC ratio is not  available, a dipstick urinalysis may be used to allow 
treatment to proceed.  
 
Thromboembolic Events: Both venous and arterial thromboembolic (TE) events, 
ranging in severity from catheter -associated phlebitis to fatal, have been reported in 
patients treated with bevacizumab in the colorectal cancer trials and, to a lesser extent, 
in patients treated with bevacizumab in NSCLC and breast cancer trials.  
 
Venous Thromboembolism (Including Deep Venous Thrombosis, Pulmonary 
Embolism, And Thrombophlebitis :  In th e phase III pi[INVESTIGATOR_47273], 
there was a slightly higher rate of venous TE events in patients treated with 
bevacizumab plus chemotherapy compared with chemotherapy alone (19% vs. 16%).  
 In Study AVF2107g, a Phase III, pi[INVESTIGATOR_47273], VTE events, including 
deep venous thrombosis, pulmonary embolism, and thrombophlebitis, occurred in 15.2% 
of patients receiving chemotherapy alone and 16.6% of patients receiving 
chemotherapy  + bevacizumab.  
 
The incidence of NCI -CTC Grade ≥ 3 venous VTE events in one NSCLC trial (E4599) 
was higher in the bevacizumab- containing arm compared to the chemotherapy control 
arm (5.6% vs. 3.2%).  One event (0.2%) was fatal in the bevacizumab- containing arm; 
not fatal events were reported in the carbopl atin/paclitaxel arm (see Bevacizumab 
Investigator Brochure).  In  metastatic CRC clinical trials, the incidence of VTE events 
   IRB#:11- 183 A  (2) 
12 
Amended: 20 -JAN -2016 
 was similar in patients receiving chemotherapy  + bevacizumab and those receiving the 
control chemotherapy alone.  
 
In clinical trials across all indications the overall incidence of VTE events was 
2.8%−17.3% in the bevacizumab- containing arms compared with 3.2% −15.6% in the 
chemotherapy control arms.  The use of bevacizumab with chemotherapy does not 
substantially increase the ris k of VTE event compared with chemotherapy alone.  
However, patients with metastatic CRC who receive bevacizumab and experienced a VTE event may be at higher risk for recurrence of VTE event.  
 Arterial Thromboembotic Events:  An increased incidence of ATE events was 
observed in patients treated with bevacizumab compared with those receiving control 
treatment.  ATE events include cerebrovascular accidents, myocardial infarction, 
transient ischemic attacks (TIAs), and other ATE events.  In a pooled analysis of  data 
from five randomized Phase II and III trials (mCRC [AVF2107g, AVF2192g, AVF0780g]; 
locally advanced or metastatic NSCLC [AVF0757g]; metastatic breast cancer 
[AVF2119g]), the incidence rate of ATE events was 3.8% (37 of 963) in patients who 
received c hemotherapy  + bevacizumab compared with 1.7% (13 of 782) in patients 
treated with chemotherapy alone.  ATE events led to a fatal outcome in 0.8% (8 of 963) 
of patients treated with chemotherapy  + bevacizumab and 0.5% (4 of 782) of patients 
treated with chemotherapy alone.  Cerebrovascular accidents (including TIAs) occurred in 2.3% of patients treated with chemotherapy  + bevacizumab and 0.5% of patients 
treated with chemotherapy alone.  Myocardial infarction occurred in 1.4% of patients 
treated with chemotherapy  + bevacizumab compared with 0.7% of patients treated with 
chemotherapy alone (see the Bevacizumab Investigator Brochure for additional details).  
 
Aspi[INVESTIGATOR_33930] a standard therapy for primary and secondary prophylaxis of arterial 
thromboembolic events in patients at high risk of such events, and the use of aspi[INVESTIGATOR_248] ≤ 
[ADDRESS_239557] to metastatic colorectal cancer patients were 
presented at ASCO 2005 (Hambleton et al., 2005). Further analyses of the effects of 
concomitant use of bevacizumab and aspi[INVESTIGATOR_51674].  
 
Gastrointestinal Perforation:  Patients with metastatic carcinoma may be at increased 
risk for the development of gastrointestinal perforation and fistula when treated with 
bevacizumab and chemotherapy. Bevacizumab should be permanently discontinued in 
patients who develop gastrointestinal perforation. A causal association of intra -
abdominal inflammator y processes and gastrointestinal perforation to bevacizumab 
treatment has not been established. Nevertheless, caution should be exercised when 
treating patients with intra- abdominal inflammatory processes with bevacizumab. 
Gastrointestinal perforation has been reported in other trials in non- colorectal cancer 
populations (e.g., ovarian, renal cell, pancreas, breast, and NSCLC) and may be higher 
in incidence in some tumor types.  
   IRB#:11- 183 A  (2) 
13 
Amended: 20 -JAN -2016 
  
Fistula:  Bevacizumab use has been associated with serious cases of fistulae including 
events resulting in death.  Fistulae in the GI tract are common (1% –10% incidence) in 
patients with metastatic CRC, but uncommon (0.1% −1%) or rare (0.01% –0.1%) in other 
indications.  In addition, fistulae that involve areas of the body other than t he GI tract 
(e.g., tracheoesophageal, bronchopleural, urogenital, biliary) have been reported 
uncommonly (0.1% –1%) in patients receiving bevacizumab in clinical studies and 
postmarketing reports.  Events were reported at various time points during treatmen t, 
ranging from 1  week to > [ADDRESS_239558], discontinuation of bevacizumab should be considered.  
 
Wound healing complications:  Wound healing compli cations such as wound 
dehiscence have been reported in patients receiving bevacizumab. In an analysis of 
pooled data from two trials in metastatic colorectal cancer, patients undergoing surgery 
28-60 days before study treatment with 5- FU/LV plus bevacizumab did not appear to 
have an increased risk of wound healing complications compared to those treated with 
chemotherapy alone (Scappaticci et al., 2005). Surgery in patients currently receiving 
bevacizumab is not recommended. No definitive data are available to define a safe 
interval after bevacizumab exposure with respect to wound healing risk in patients 
receiving elective surgery; however, the estimated half life of bevacizumab is 21 days. 
Bevacizumab should be discontinued in patients with severe wound healing 
complications.  
 If patients receiving treatment with bevacizumab require elective major surgery, it is 
recommended that bevacizumab be held for 4 -8 weeks prior to the surgical procedure.  
Patients undergoing a major surgical procedure should not begin or restart bevacizumab 
until 4 weeks after that procedure (in the case of high -risk procedures such as liver 
resection, thoracotomy, or neurosurgery, it is recommended that chemotherapy be 
restarted no earlier than 6 weeks and bevacizumab no earlier than 8 weeks after 
surgery).  
 
Hemorrhage : Overall, grade 3 and 4 bleeding events were observed in 4.0% of 1132 
patients treated with bevacizumab in a pooled database from eight phase I, II, and III 
clinical trials in multiple tumor types (bevacizumab Inves tigator Brochure, October 2005). 
The hemorrhagic events that have been observed in bevacizumab clinical studies were 
predominantly tumor -associated hemorrhage (see below) and minor mucocutaneous 
hemorrhage.  
 
Tumor -Associated Hemorrhage:   Major or massive pulmonary hemorrhage or 
hemoptysis has been observed primarily in patients with NSCLC.  Life- threatening and 
fatal hemoptysis was identified as a bevacizumab- related adverse event in NSCLC trials.  
These events occurred suddenly and presented as major or m assive hemoptysis.  
Among the possible risk factors evaluated (including squamous cell histology, treatment 
with anti -rheumatic/anti -inflammatory drugs, treatment with anticoagulants, prior 
radiotherapy, bevacizumab therapy, previous medical history of atherosclerosis, central 
   IRB#:11- 183 A  (2) 
14 
Amended: 20 -JAN -2016 
 tumor location, and cavitation of tumors during therapy), the only variables that showed 
statistically significant correlations with bleeding were bevacizumab therapy and 
squamous cell histology.  
 In Study E4599, in which squamous cel l carcinoma was excluded, the rate of any type of 
Grade ≥ 3 hemorrhage was 1.0% in the control arm (carboplatin and paclitaxel) versus 
4.1% in the carboplatin and paclitaxel  + bevacizumab arm (Sandler et al. 2006).   
 
GI hemorrhages, including rectal bleeding and melena have been reported in patients 
with CRC, and have been assessed as tumor -associated hemorrhages.  
 
Tumor -associated hemorrhages were also seen rarely in other tumor types and 
locations, including a case of CNS bleeding in a patient with hepatoma with occult CNS 
metastases and a patient who developed continuous oozing of blood from a thigh 
sarcoma with necrosis.  
 
Mucocutaneo us Hemorr hage:  Across all bevacizumab clinical trials, mucocutaneous 
hemorrhage has been seen in 20% -40% of patients  treated with bevacizumab. These 
were most commonly NCI -CTC Grade [ADDRESS_239559] also been less common events  of minor mucocutaneous hemorrhage in 
other locations, such as gingival bleeding and vaginal bleeding.  
 
Reversible Posterior Leukoencephalopathy Syndrome:   There have been rare 
reports of bevacizumab- treated patients developi[INVESTIGATOR_200906], a rare neurologic disorder that can present with the following 
signs and symptoms (among others):  seizures, headache, altered mental status, visual 
disturbance, or cortical blindness, with or without associated hypertension.  Brain 
imaging is mandatory to confirm the diagnosis of RPLS.  In patients who develop RPLS, 
treatment of specific symptoms, including control of hypertension, is recommended 
along with discontinuation of bevacizumab.  The safety of reinitiating bevacizumab 
therapy in patients previously experiencing RPLS is not known (Glusker et al. 2006; 
Ozcan et al. 2006).   
 
Congestive Heart Failure:   In clinical trials CHF was observed in all cancer indications 
studied to date, but predominantly in patients with metastatic br east cancer.  In the 
Phase III clinical trial of metastatic breast cancer (AVF2119g), 7 (3%) bevacizumab-
treated patients experienced CHF, compared with two (1%) control arm patients.  
These  events varied in severity from asymptomatic declines in left vent ricular ejection 
fraction (LVEF) to symptomatic CHF requiring hospi[INVESTIGATOR_47276].  All the patients treated with bevacizumab were previously treated with anthracyclines 
(doxorubicin cumulative dose of 240− 360 mg/m
2).  Many of these patients also had prior 
radiotherapy to the left chest wall.  Most of these patients showed improved symptoms 
and/or left ventricular function following appropriate medical therapy  (Miller et al. 2005).  
 
In a randomized, Phase III trial of patients with previously untr eated metastatic breast 
cancer (E2100), the incidence of LVEF decrease (defined as NCI -CTC Grade 3 or 4) in 
the paclitaxel  + bevacizumab arm was 0.3% versus 0% for the paclitaxel alone arm . 
   IRB#:11- 183 A  (2) 
15 
Amended: 20 -JAN -2016 
   
No information is available on patients with preexisting CHF of [LOCATION_001] Heart 
Association (NYHA) Class II −IV at the time of initiating bevacizumab therapy, as these 
patients were excluded from clinical trials.  
 
Prior anthracyclines exposure and/or prior radiotherapy to the chest wall may be 
possible risk factors for t he development of CHF.  Caution should be exercised before 
initiating bevacizumab therapy in patients with these risk factors.  
 
A Phase II trial in patients with refractory acute myelogenous leukemia reported 5  cases 
of cardiac dysfunction (CHF or LVEF dec rease to < 40%) among 48  patients treated with 
sequential cytarabine, mitoxantrone, and bevacizumab.  All but 1 of these patients had significant prior exposure to anthracyclines as well (Karp et al. 2004).  
 
Other studies in patients with various tumor types and either a history of anthracycline 
exposure or concomitant use with bevacizumab are ongoing.  
 Patients receiving concomitant anthracyclines or with prior exposure to anthracyclines 
should have a baseli ne MUGA scans or echocardiograms (ECHOs) with a normal LVEF.  
 
Neutropenia:   Increased rates of severe neutropenia, febrile neutropenia, or infection 
with severe neutropenia (including some fatalities) have been observed in patients 
treated with some myelot oxic chemotherapy regimens plus bevacizumab in comparison 
to chemotherapy alone ( Sandler et al. 2006 ). 
 
Additional Adverse Events:   See the bevacizumab Investigator Brochure for additional 
details regarding the safety experience with bevacizumab.  
 
Likely (  > 20%)  Less Likely ( ≤ 20%)  Rare  but Serious ( < 3%)  
• Hypertension  
• Reproductive 
system and breast 
disorders -
Other(ovarian 
failure)10 
• Thrombocytopenia  
• Lymphopenia  • Anemia  
• Febrile neutropenia  
• Supraventricular tachycardia 
• Vertigo  
• Abdominal Pain  
• Colitis  
• Constipation  
• Diarrhea  
• Dyspepsia  
• Gastrointestinal hemorrhage2 
• Gastrointestinal obstruction3  
• Ileus  
• Mucositis oral  
• Nausea  
• Vomiting  
• Fatigue  
• Infusion related reaction  
• Non- cardiac chest pain   
• Pain 
• Allergic reaction  
• Infection6 • Blood and lymphatic system 
disorders -Other (re nal 
thrombotic microangiopathy)  
• Acute coronary syndrome 
• Heart f ailure  
• Left v entricular systolic       
 dysfunction  
• Myocardial infarction  
• Ventricular arrhythmia 
• Ventricular fibrillation  
• Gastrointestinal fistula1 
• Gastrointestinal perforation4 
• Gastrointestinal ulcer5 
• Anaphylaxis  
• Gastrointestinal anastomotic    
leak 
• Intracranial hemorrhage  
• Ischemia cerebrovascular  
• Reversible posteri or  
leukoencephalopathy syndrome  
• Acute kidney injury  
   IRB#:11- 183 A  (2) 
16 
Amended: 20 -JAN -2016 
 • Infections and infestations -Other 
(peri-rectal abscess)  
• Wound dehiscence  
• Alanine aminotransferase increased  
• Alkaline phosphatase increased  
• Aspartate aminotransferase 
increased  
• Blood bilirubin increased  
• Cardiac troponin I increased 
• Neutrophil count decreased  
• Weight loss  
• White blood cell decreased  
• Anorexia  
• Arthralgia  
• Musculoskeletal and connective 
tissue disorder -Other (bone 
metaphyseal dysplasia)7 
• Myalgia 
• Osteonecrosis of jaw8 
• Dizzin ess 
• Headache  
• Peripheral sensory neuropathy9 
• Syncope  
• Hematuria 
• Proteinuria  
• Vaginal hemorrhage  
• Allergic rhinitis  
• Cough  
• Dyspnea  
• Epi[INVESTIGATOR_3940]  
• Hoarseness  
• Pruritus  
• Rash maculo- papular  
• Urticaria  
• Thromboembolic event  • Renal and urinary disord ers-
Other (Nephrotic Syndrome)  
• Urinary fistula  
• Vaginal fistula  
• Bronchopleural fistula, 
Bronchopulmonary hemorrhage  
• Respi[INVESTIGATOR_200907] - Other 
(nasal -septal perforation)   
• Respi[INVESTIGATOR_200908] - Other 
(tracheo- esophageal fistula)  
• Vascular disorders -Other 
(arterial thromboembolic event)**
11 
• Cellulitis  
• Posterior reversible encephalopathy syndrome 
(PRES)  
• Non- mandibular osteonecrosis  
• Fetal abnormalities  
 
1Gastrointestinal fistula may include: Anal fistula, Colonic fistula, Duodenal fistula, Esophageal 
fistula, Gastric fistula, Gastrointestinal fistula, Rectal fistula, and other sites under the 
GASTROINTESTINAL DISORDERS SOC.  
 
2Gastrointestinal hemorrhage may include:  Colonic hemorrhage, Duodenal hemorrhage, 
Esophageal hemorrhage, Esophageal varices hemorrhage, Gastric hemorrhage, Hemorrhoidal 
hemorrhage, Intra -abdominal hemorrhage, Oral hemorrhage, Rectal hemorrhage, and other 
sites under the GASTROINTESTINAL DISORDERS SOC.  
 
3Gastrointestinal obstruction may include:  Colonic obstruction, Duodenal obstruction, 
Esophageal obstruction, Ileal obstruction, Jejunal obstruction, Rectal obstruction, Small intestinal obstruction, and other sites under the GASTROINTESTINAL DISORDERS SOC.  
 
4Gastrointestinal perforation may include:  Colonic perforation, Duodenal perforation, 
Esophageal perforation, Gastric perforation, Jejunal perforation, Rectal perforation, Small intestinal perforation, and other sites under the GASTROINTESTINAL DISORDERS SOC.  
   IRB#:11- 183 A  (2) 
17 
Amended: 20 -JAN -2016 
  
5Gastrointestinal ulcer may include:  Duodenal ulcer, Esophageal ulcer, Gastric ulcer, and other 
sites under the GASTROINTESTINAL DISORDERS SOC.  
 
6Infection may include any of the [ADDRESS_239560] active epi[INVESTIGATOR_170675].  
 
8Cases of osteonecrosis of the jaw (ONJ) have been reported in cancer p atients in association 
with bevacizumab treatment, the majority of whom had received prior or concomitant treatment 
with i.v. bisphosphonates.  
 
9Increased rate of peripheral sensory neuropathy has been observed in trials combining 
bevacizumab and chemother apy compared to chemotherapy alone.  
 
10Ovarian failure, defined as amenorrhea lasting 3 or more months with follicle- stimulating 
hormone (FSH) elevation (≥30 mIU/mL), was increased in patients receiving adjuvant 
bevacizumab plus mFOLFOX compared to mFOLFOX alone (34% vs. 2%).   After 
discontinuation of bevacizumab, resumption of menses and an FSH level <30 mIU/mL was 
demonstrated in 22% (7/32) of these women.   Long term effects of bevacizumab exposure on 
fertility are unknown.  
 
11Arterial thromboembol ic event includes visceral arterial ischemia, peripheral arterial ischemia, 
heart attack, and stroke.  
 
**In the AVF2107study [36, 37], there was a 1% incidence of arterial thromboembolic events 
(which include myocardial ischemia/infarction, transient ischemia attack, cerebrovascular 
accident/stroke and angina/unstable angina) in the IFL + placebo arm versus 3% in the IFL + 
bevacizumab arm. A pooled analysis of the rate of arterial TE events from 5 randomized studies 
showed that treatment with bevacizumab increased the risk of these events two- to-three fold (up 
to 5%). Furthermore, certain baseline characteristics, specifically age> 65 years and prior 
arterial TE event, conferred additional risk . 
 Also reported on Bevacizumab (rhuMAb VEGF) trials but with the relationship to 
Bevacizumab (rhuMAb VEGF) still undetermined:  
 
- Blood and lymphatic system disorders -  Other (idiopathic thrombocytopenia purpura)  
- Disseminated intravascular coagulation  
- Pericardial effusion 
- Gait disturbance  
- Sudden death NOS  
- Hepatic failure  
- Infections and infestations -  Other (aseptic meningitis)  
- Platelet count decreased  
- Hyponatremia 
- Musculoskeletal and connective tissue disorder - Other (aseptic necrotic bone)  
- Musculoskeletal and connective tissue disorder - Other (myasthenia gravis)  
- Dysgeu sia 
   IRB#:11- 183 A  (2) 
18 
Amended: 20 -JAN -2016 
 - Peripheral motor neuropathy  
- Seizure  
- Confusion 
- Adult respi[INVESTIGATOR_1505]  
- Pneumonitis  
- Pneumothorax  
- Pulmonary hypertension 
- Palmar -plantar erythrodysesthesia syndrome  
- Skin ulceration  
 
Note : Bevacizumab (rhuMAb VEGF) in combination with other agents could cause an 
exacerbation of any adverse event currently known to be caused by [CONTACT_6767], or 
the combination may result in events never previously associated with either agent  
 
1.3 Other Study Drug(S) Background  
 a. Cyclophosphamide And Topotecan 
As single agents, cyclophosphamide and topotecan are used in the treatment of a 
variety of pediatric tumors. The combination of cyclophosphamide and topotecan has 
been demonstrated to be an active chemotherapeutic regimen for treatment of 
relapsed/refr actory Ewing sarcoma, rhabdomyosarcoma, neuroblastoma, Wilms’ tumor, 
germ cell tumors, and brain tumors.
[ADDRESS_239561] had prior 
exposure to this agent. Patients ≥ [ADDRESS_239562] risk medulloblastoma are 
often treated with vincristine, cisplatin and lomustine (without cyclophosphamide), and 
patients ≥ [ADDRESS_239563]. Jude investig ators to be active versus medulloblastoma in a phase II window 
study when administered as a 30 minute infusion daily x 5 days, as will be used in this study.
27 Using a 72- hour infusion schedule of topotecan, Pediatric Oncology Group 
(POG) investigators rep orted that 5 of 17 patients with ependymoma achieved stable 
disease.28 Children’s Cancer Study Group (CCG) investigators performed a phase I 
study using a 21 -day continuous infusion and reported that 2 of 3 patients with 
ependymoma achieved objective responses.29 
 
This study will focus primarily on the evaluation of the efficacy of the combination CTB in 
a restricted  group of pediatric cancer patients, those with diagnoses of Ewing’s sarcoma 
and neuroblastoma. Prior data in patients with Ewing’s sarcoma and neuroblastoma 
have demonstrated efficacy in second line therapy with the combination 
cyclophosphamide and topotecan, both agents known to demonstrate single agent activity in these diseases. Importantly, o bjective response data has been published in 
children with neuroblastoma and Ewing’s sarcoma at the time point indicated in the primary study objective of this study , after 2 cycles of therapy, which can be used for 
comparison,  Saylors et al reported response rates after 2 cycles of 
   IRB#:11- 183 A  (2) 
19 
Amended: 20 -JAN -2016 
 cyclophosphamide/ topotecan as  4/13 ( 30.8% ) for neuroblastoma patients and 5/17 
(29.4% ) Ewing’s sarcoma patients. Given the similar response rates (~30%) in   
historical phase II data with the chemotherapy backbone cyclophosphamide and 
topotecan , it was decided that the disease types neuroblastoma and Ewing’s sarcoma 
would be evaluated in a single cohort .[ADDRESS_239564] 
frontline chemotherapy for patients with Ewing’s sarcoma consis ts of the agents of 
vincristine, ifosfamide, doxorubicin, dactinomycin, and etoposide. Standard frontline 
chemotherapy for patients with neuroblastoma consists of the agents, cyclophosphamide, doxorubicin, vincristine, cisplatin, etoposide in combination w ith 
immunotherapy consisting of a monoclonal antibody directed to GD2. Given the limited 
overlap with first line therapy, it is anticipated that there will be activity as well in this trial.  
 
1.4 Study Rationale   
This study will evaluate the safety and eff icacy of the chemotherapeutic regimen 
cyclophosphamide and topotecan in combination with the novel agent bevacizumab 
(CTB). The schedule that will be used will be the 5- day infusion schedule every [ADDRESS_239565], prostate, 
rhabdomyosarcoma, and Wilms’ tumor. Synergism with standard cytotoxic agents has 
been demonstrated including cyclophosphamide and topotecan. We hypothesize that 
the addition of bevacizumab to the standard regimen cyclophosphamide and topotecan 
will show enhanced clinical efficacy without additive toxicity.  
 
In this study, we propose a novel schedule of administration of bevacizumab which may 
enhance the effect of cytotoxic chemotherapy with cyclophosphamide and topotecan. 
Bevacizumab will be administered [ADDRESS_239566] effective when given several days prior to 
conventional chemotherapeutic delivery at a time when tumor blood vessel 
“normalization” and drug delivery are most optimal.33 This window of vessel 
normalization allows for greater influx or convection of chemotherapeutic agents into the tumor which is associated with a decrease in interstitial hypertension and peritumoral 
   IRB#:11- 183 A  (2) 
20 
Amended: [ADDRESS_239567] a precise regulation of the spatial and temporal expression of VEGF is required for normal vasculature.  VEGF blockade has been shown to prune immature and leaky vessels with 
resultant decrease in interstitial hypertension, peri -tumor edema. Recent studies by 
[CONTACT_200942]. 
34 After a single dose of bevacizumab, a 
progressive decrease in tumor  microvessel density in established orthotopic 
neuroblastoma xenografts was reported to < 30% of control was observed within [ADDRESS_239568] -enhanced ultrasonography, was improved, although 
this latter change abated by 1 week. Intratumoral drug delivery mirrored these changes. 
Penetration of chemotherapy was improved by 81% when given 1- 3 days after 
bevacizumab compared with when both drugs were given concomitantly or 7 days apart. Administration of topotecan to tumor -bearing mice 3 days after bevacizumab resulted in 
greater tumor inhibition (36% of control size)  than with monotherapy (88% bevacizumab, 
54% topotecan) or concomitant administration of the two drugs (44%). These findings 
provide the rationale for the novel schedule of administration of bevacizumab proposed 
in this trial in which bevacizumab will admi nistered 3 days prior to conventional 
chemotherapy.  
 
1.5 Rationale For Correlative Studies 
This study will also include several mandatory exploratory biologic correlative studies to 
help determine the angiogenic profile of patients at baseline and following treatment with the bevacizumab- containing cytotoxic chemotherapy regimen.  
 1.5.1 Rationale for Investigating EPCs/HPCs 
All tumors require their own blood supply through several means including angiogenesis -
coopti on, branching from the existing vasculature, and vasculogenesis -recruitment of de 
novo single cells similar to processes observed in embryonic development.   
 
In response to VEGF -A and PlGF (placental growth factor, which signals via VEGFR1 
only) EPCs and HPCs proliferate and mobilize fr om the bone marrow into the circulation 
for recruitment to the primary tumor .
35, 36 This “angiogenic switch”, supports an extensive 
vasculature network and has been shown to be associated with a worse prognosis .37, 38 
In particular, VEGFR1+ CD68+ stromal h emangiocytes within tumor tissue correlated with 
more aggressive subtypes of Non- Hodgkins lymphoma.39 Similarly, VEGFR1 and 
VEGFR2 expression with solid tumors has been associated with more aggressive stage (Ref).  Early myeloid HPCs as well as tumor -assoc iated myeloid cells and macrophages 
(TAMs) have been shown to migrate along blood vessels promoting tumor cell extravasation and invasion into adjacent tissue. These myeloid cell infiltrates have been 
associated with higher stage tumors and worse prognosis .
 36, [ADDRESS_239569] additional roles in local invasion since these cells are commonly present at the 
peripheral rim of tumors, a site known as the invasive front.71  Because of their critical 
contribution to primary tumor growth and invasion, these bone marrow -derived 
progenitor cells may also participate in metastasis.    
   IRB#:11- 183 A  (2) 
21 
Amended: 20 -JAN -2016 
  
At distant sites of future metastasis, bone marrow -derived VEGFR1+ HPCs have been 
identified prior to evidence of tumor cell spread which establish a conducive microenvironment termed by [CONTACT_200943] “pre- metastatic niche” .
 40 Following the 
arrival of tumor cells, VEGFR2+ EPCs contribute to new blood vessel formation in 
micrometastases leading to progression of the metastatic lesions.  
 
Conceivably, HPCs ma y support tumor cell homing in other niches, such as in the bone 
marrow microenvironment possibly favoring dormancy or promoting relapse of residual tumor cells.  As these bone marrow -derived cells are important in tumor invasion and 
metastasis, HPCs and E PCs can potentially represent prognostic indicators obtained not 
only from tissue samples, but also from the blood.  The biology of mobilization of HPCs and EPCs during tumorigenesis and metastasis therefore makes enumeration of these 
cells in circulation ideal surrogate markers to assess response to VEGF- A targeted 
therapi[INVESTIGATOR_014].   
 
VEGFR2
+ circulating EPCs are elevated in the blood of patients in several adult cancers 
including breast cancer and lung cancer.41, [ADDRESS_239570] colon cancer recurrence . 44 Recently work has been 
performed in adult patients with non- Hodgkin’s lymphoma that demonstrated elevations 
in CEPs in patients compared to controls and these levels correlated with treatment 
response. 45 
 
There is limited information utilizing VEGFR1+ HPC levels as a biomarker for malignant 
disease. Howev er, preclinical preliminary data from our laboratory shows that there is 
elevation in HPCs in pediatric patients with rhabdomyosarcoma and adult patients with 
breast cancer compared to healthy controls and these levels correlate with more 
advanced disease and treatment response (Figure 2 & Table 1).  Furthermore, recent 
work by [CONTACT_200944] a high -risk group of gastric cancer patients 
can be identified by [CONTACT_200945] -[ADDRESS_239571] that this marker may be useful in 
determining risk of recurrence and may be useful in assessing treatment response by 
[CONTACT_200946]1+ HPC levels in pediatric patients with solid tumors receiving 
treatment with Bevacizumab and other anti -angiogenic agents.  We believe that using 
circulating VEGFR2+ EPCs and VE GFR1+ HPCs in combination will prove to be a 
powerful biomarker tool and guide risk stratification, treatment decisions and timing and 
duration of therapy.     
  
   IRB#:11- 183 A  (2) 
22 
Amended: [ADDRESS_239572] approach to timing and duration of therapy.   Genetic analysis of these cells may also uncover new anti -angiogenic targets as well . 
  
1.5.2 Soluble Markers Of Angiogenesis For The Assessment Of Biological Activity   
          During Bevacizumab Based Therapy  
Tumor regression in response to agents such as bevacizumab is usually measured by [CONTACT_79595]- invasive
 imaging techniques such as computed tomography (CT) and 
magnetic resonance imaging (MRI). However, because of the cost and the patient 
inconvenience involved such techniques are not feasible for regular target modulation 
analysis. In contrast, the measurement of serum and plasma angiogenic biomarkers 
offers an alternative approach to assess biological responses during treatment.  
Previous studies have shown that several soluble molecules including VEGF, basic 
fibroblast growth factor (bFGF) and several endothelial cell-associated molecules 
provide an effective biomarker profile in response to targeted anti -angiogenic agents . 47-
[ADDRESS_239573] the hypoxic status of a tumor and may increase in respons e to 
effective blockade of VEGF receptors.  
 
Abnormalities in other plasma indices of angiogenesis, such as angiopoietins (Ang- 1, 
Ang-2), as well as the soluble receptors Flt -1 (sFlt -1) and Tie 2 (sTie- 2) have also been 
shown to correlate with a tumors res ponse to the blockade of VEGF activity. 50, [ADDRESS_239574] been shown to upregulate a number 
of other angiogenic growth factors, including placenta growth factor (PlGF), in a tumor -
specific pattern. Hence following the expression of PlGF in patients undergoing 
antiangiogenic treatment provides an avenue to identify treatment effectiveness . 52 
Though not comprehensive, we hypothesize that including the measurement of the 
expression of angiogenic factors (VEGF, bFGF) , angiopoietins (Ang -1, Ang -2), 
angiogenesis modulators (sVEGFR, sTie -2) and angiogenesis enhancers (PlGF) will 
provide specific and sensitive biomarker profile on the action of bevacizumab and offer 
important clinical correlative analysis.  
 
1.5.3 Understanding Tumor -Related Processes Through Metabolic Profiling .   
Metabolic profiling can be used to differentiate between different cancer cell lines and to 
monitor metabolic processes in cancer cells during apoptosis.  Metabolomics has been 
used to study the changes in hypoxic regions of tumors that develop when a tumor 
outgrows its vasculature. 60 In such tumors, over -expression of hypoxia inducible factor 
(HIF-1) co -exists with increased glucose transporters, glycolytic enzymes and growth 
facto rs (such as VEGF).  The rate of glycolysis by [CONTACT_200947].  Previous studies with anti -mitotic drugs show the decreased bioenergetic 
status of the tumor is accompanied by [CONTACT_200948]. 61 With a novel 
targeted agent (imatinib for BCR -ABL inhibition, for example), the metabolic signature [CONTACT_201004]#:11- 183 A  (2) 
23 
Amended: [ADDRESS_239575] the relative contribution that each individual agent makes within the treatment regimen.  Plasma levels of each drug will be determined at defined time points 
throughout protocol therapy.  At defined time- points, MRI scanning will be conducted in 
conjunction with blood sampling for MR spectroscopy.  Tumor and normal tissues /bone 
marrow can be used for Western blot and gene expression analysis, as is appropriate for normal clinical care of pediatric patients with refractory cancers.  For patients who do not 
require biopsies for their general clinical care, peripheral blood specimens can be 
evaluated.  
 These experiments reveal how the combination of bevacizumab, cyclophosphamide and 
topotecan affects the bioavailability, metabolic and biochemical, and anti -tumor activity 
of each of the component drugs in vivo . MRI/NMR assessment will be of special interest, 
because at the current time, there are no data regarding non- invasive techniques for 
measuring metabolic response to treatment in pediatr ic tumors.   
 
1.5.[ADDRESS_239576] been additional cases reported 
following treatment with bevacizumab in children and adults; however, follow -up has 
been limited.  In this study, patients will be monitored for changes in the growth plates 
related to treatment with bevacizumab.  
 
2.0 OBJECTIVES  
 
2.1 Primary   
2.1.1  To determine the efficacy of the bevacizumab in combination with 
cyclophosphamide and topotecan (CTB) in patients with relapsed/refractory  
Ewing’s Sarcoma and n euroblastoma as m easured by [CONTACT_20363] 
(CR/PR)  after 2 cycles of treatment  and duration of response.  
 
2.2 Secondary   
2.2.1  To evaluate the safet y and tolerability of bevacizumab in combination with   
           cyclophosphamide and topotecan.  
 
2.2.2  To determ ine the efficacy of combining bevacizumab with cyclophosphamide and  
           topotecan by [CONTACT_188169] (OS) and time to progression (TTP).  
 
2.2.3 To determine the pharmacokinetic profile of bevacizumab when combined with  
           cyclophosphamide and topotecan.  
   IRB#:11- 183 A  (2) 
24 
Amended: 20 -JAN -2016 
  
2.3  Exploratory  
2.3.1  To determine the expression of angiogenesis associated biomarkers in serum in  
            patients with relapsed/refractory Ewing’s sarcoma and neuroblastoma treated    
            with CTB.  
 
2.3.2  To determine the angiogenic profile of relapsed/ refractory Ewing’s  sarcoma and  
            neuroblastoma treated with CTB.  
 
2.3.[ADDRESS_239577] effective when given several days prior to conventional chemotherapeutic delivery to allow for normalization of tumor blood 
vessels. The chemotherapy is then administered at a time when tumor blood vessel “normalization” and drug delivery are most optimal. This window of vessel normalization 
allows for greater influx or convection of chemotherapeutic agents into the tumor which 
is associated with a decrease in interstitial hypertension and peritumoral edema and 
therefore a reduction in the efflux or convection out of the tumor of chemotherapy 
allowing for greater effect as well as growth factors, and cancer cells  form the tumor 
margins reducing metastatic dissemination. It is hoped that this schedule may impact ultimately on efficacy of this combination. This study will also incor porate bevacizumab 
at the standard dose established in adult and pediatric trials of 1 5 mg/ Kg IV Q 3 weeks 
that was demonstrated to be safe.  In the event of inordinate toxicity, the dose of 
Bevacizumab will be eliminated. Cyclophosphamide and topotecan will be administered 
at a fixed dose according to the conventional 5- day schedule of ad ministration.  
 
3.2.2  The tumor types to be evaluated in this study will in corporate tumors for which 
similar historical  efficacy data is available  including Ewing’s sarcoma and 
neuroblastoma.  
 
 
   IRB#:11- 183 A  (2) 
25 
Amended: 20 -JAN -2016 
 3.3  Outcome  Measures  
3.3.1  Primary Outcome Measures  
The primary efficacy endp oint will be the objective response rate (CR/PR)  after [ADDRESS_239578] guideline 
(version 1.1) . Patients who experience progression of disease prior to receiving the 
second cycle of therapy will be considered a treatment failure. If appropriate, patients 
may be evaluated by [CONTACT_200949] ( e.g., neuroblastoma). 
The variables will be the tumor measurements and assessment of non- target lesions by 
[CONTACT_200950].  
 
3.3.2  Secondary Outcome Measures 
Secondary efficacy endpoints will include time to tumor progression, progression- free 
survival , and evaluation of pharmacodynamic parameters. Duration of disease 
stabilization will also be assessed.  
 
3.3.3  Safety Outcome Measures 
Safety Assessment Methods  
Safety will be assessed by [CONTACT_5292], interim history, and laboratory 
assessments. Adverse events will be graded according to the NCI -CTCAE, version 4 .0  
 
Safety Laboratory Assessments  
The local laboratory of the institution where the trial is being conducted will be used to 
process the laboratory results. Clinically significant laboratory abnormalities (e.g., those 
that lead to some sort of intervention) are to be assessed as adverse ev ents and 
recorded on the appropriate CRF.  
 
Patients will be considered evaluable for response if they have received at least [ADDRESS_239579] one cycle of treatment. 
 
4.0 SAFETY PLAN  
See Section 4.1 for complete details of the safety evaluation for this study.  
 
4.1 General Plan To Manage Safety   
a. Bevacizumab -Specific 
A number of measures will be taken to ensure the safety of patients participating in this 
trial.  These measures will be addressed through exclusion criteria (see Section 5.3) and 
routine monitoring as follows.  
 Patients enrolled in this study will be evaluated clinically and with standard laboratory 
tests before and at regular intervals during their participation in this study.  Safety 
evaluations will consist of medical interviews, recording of adverse events, physical 
examinations, blood pressure, and laboratory measurements (performed by [CONTACT_102127], see Section  8.0).  Patients  will be evaluated for adverse events (all grades), 
serious adverse events, and adverse events requiring study drug interruption or 
discontinuation at each study visit for the duration of their participation in the study.  
   IRB#:11- 183 A  (2) 
26 
Amended: 20 -JAN -2016 
 Patients discontinued from the treatment phase of the study for any reason will be 
evaluated ~30 days (28 –42 days) after the decision to discontinue treatment (see 
Section 7.1.3).    
Specific monitoring procedures are as follows:  
 
1. Hypertension: Hypertension will be monitored through routine evaluation of blood 
pressure prior to each bevacizumab treatment.  Optimal control of blood pressure according to standard public health guidelines is recommended for patients on treatment 
with or without bevacizumab.  Patients who develop hypertension while on study, as 
defined by [CONTACT_200951] ≥ 140 and/or diastolic BP ≥ 90 mmHg, or greater than 20% above 
upper limit of normal ( ULN) for age, should be treated with appropriate medical therapy, 
initially with a single agent antihypertensive medication.  A second antihypertensive agent should be added if suboptimal control continues.  For controlled hypertension 
(sBP <140 and/or dBP  < 90 mmHg or less than 20% above ULN for age), patients may 
continue study treatment without interruption. For persistent or symptomatic 
hypertension, defined as ≥ grade 2, despi[INVESTIGATOR_200909], bevacizumab must be 
held until hypertension is ≤ grade 1.  Patients with grade 4 hypertension (hypertensive 
crisis) or hypertension that persists despi[INVESTIGATOR_200910].  Refer to Appendix G for normal values for blood 
pressure in children.  
 
2. Proteinuria:  Proteinuria will be monitored by [CONTACT_39701]:  creatinine (UPC) ratio 
or dipstick at screening, Day 0 of therapy and every 2 cycles before the next dose of 
Bevacizumab. For patients with ≥  2+ protein by [CONTACT_5230]  (for younger patients refer to 
CTCAE V4.0 f or values)  on Day 0  and subsequent testing after in itiation of study 
therapy, bevacizumab therapy will be held and a 24- hour urine collection will be 
performed for total protein analysis. If the 24 -hour urine protein is <  2 g, then the patient 
may continue bevacizumab therapy at the same dose without interruption.  If the urine 
protein is 2- 3 g/24 hours, bevacizumab therapy will be held for one week, and a 24- hour 
urine collection will be repeated.  Treatment with bevacizumab may be reinstituted after 
a one or two week delay if the 24 hour protein is <  2 g/[ADDRESS_239580] the hypothesis  of this study .  
Patients will be discontinued from the study therapy if the 24 -hour protein is >  3 g/24 
hours, if there is a second 24 hour urine protein >  2 g, or if the 24- hour urine protein 
does not decrease to <  2 g/24 hours after a 2 week delay of do sing. Patients will be 
discontinued from the study therapy if the 24 -hour protein is >  3 g/24 hours, if there is a 
second 24 hour urine protein >  2 g, or if the 24 -hour urine protein does not decrease to <  
2 g/24 hours after a 2 week delay of dosing.  
 
3. Elective major surgery: If patients on treatment with bevacizumab require elective 
major surgery, it is recommended that bevacizumab be held for 4 -8 weeks prior to the 
surgical procedure. Patients undergoing a major surgical procedure should not 
begin/restart bevacizumab until 4 weeks after that procedure (in the case of high risk 
procedures such as liver resection, thoracotomy, or neurosurgery, it is recommended 
that treatment with the chemotherapy combination, CTB should be restarted no earlier 8 
wk after sur gery).  
 
   IRB#:11- 183 A  (2) 
27 
Amended: 20 -JAN -2016 
 b. Other Study Drug(s) -Specific  
Please see Section 7.1.3 for detailed instructions for the management of study drug –
related toxicities.  
 
5.[ADDRESS_239581] Selection  
Investigators will be expected to maintain a screening log of all potential study 
candidates that includes limited information about the potential candidate (ie. age, sex, 
date) and the out come of the screening process ( ie. enrolled into study, reason for 
ineligibility, or refusal to participate).   
 
Screening Failures :  
Patients who fail to meet the inclusion and/or exclusion criteria are defined as screen 
failures. For all screen failur es, the investigator will document  the patient initials and 
reason(s) for screen failure in the screening log . A copy of the log should be retained in 
the investigator’s study files.  
 
5.2 Inclusion Criteria  
Patients will be included in the study based on the following criteria:  
 
5.2.[ADDRESS_239582] histologically confirmed relapsed/ref ractory Ewing’s sarcoma  
or neuroblastoma.   
 
5.2.[ADDRESS_239583] measurable disease (Refer to Section [IP_ADDRESS] for the 
definition of measurable disease.)  Patients with a diagnosis of neuroblastoma 
with MIBG avid disease only are permitted to enroll on this study.  
 
5.2.[ADDRESS_239584] be ≤ 21 years of age at time of diagnosis  
 
5.2.4  Life expectancy ≥  3 months  
 
5.2.5  Lansky or Karnofsky performance ≥ 70% 
 5.2.6  Written informed consent  
 
5.2.7  Organ and marrow function defined as follows:  
Hematologic function, as follows  
- Absolute neutrophil count  ≥  1000/µL  
- Platelets ≥ 100 x 109/L (without transfusion < 14 days before enrollment)  
- Hemoglobin ≥ 9 gm/dl  
 
Renal function, as follows :  
- Serum creatinine ≤ ULN for age. Refer to Appendix H for normal values for 
serum creatinine in children.  
   IRB#:11- 183 A  (2) 
28 
Amended: [ADDRESS_239585] be ≥ 60 ml/min/1.73 m2 
- Urinary protein < 2+ (unless total quantitative protein is < 5 00 mg protein/day 
as determined by 24 H urine collection) . for pediatr ic patients please refer to 
the CTCAE V4.0 for values.  
Hepatic function, as follows :  
- Total bilirubin ≤  1.5x ULN  
- AST and ALT ≤ 2.5x ULN for institution or ≤ 5x ULN for institution if 
clearly attributable to liver metastases  
- Albumin ≥ 2.5 g/dl.  
 
Coagulation : INR ≤ 1.5x ULN.  
 
5.2.8  Prior T reatment : Patients must have recovered from the acute toxic effects of all 
prior chemotherapy, immunotherapy, or radiation therapy prior to entry on study. 
Patients must have had at least one prior treatment regimen.  Patients may  have 
received treatment previously with cyclophosphamide, topotecan,  or 
bevacizumab.  
Myelosuppressive chemotherapy : Two weeks must have elapsed since 
administration of previous chemotherapy.  
Biologic agents : At least [ADDRESS_239586] dose of retinoids.  
Radiation therapy : For all patients, ≥ [ADDRESS_239587] elapsed for local XRT; ≥ 
[ADDRESS_239588] elapsed if pri or radiation to ≥ 50% of the pelvis or if 
substantial bone marrow irradiation.  Patients with a history of prior radiation with 
field including the heart (e.g. mantle) will be excluded.  
Stem cell transplant : Patients who have undergone prior stem cell transplantation 
will not be excluded from study entry. At least [ADDRESS_239589] disease.   
 
5.3  Exclusion Criteria  
a. Disease -Specific Exclusions  
5.3.1  Disease -Specific Exclusions  
• Patients with centrally -located pulmonary or mediast inal primary tumors or 
metastases adjacent to or invading large blood vessels.  
• Prior left chest wall irradiation or a cumulative ant hracycline  dose of greater or 
equal to 300 mg/m2, unless the ejection fraction or fraction shortening is within 
normal institutional limits, in which case the patient can be enrolled.  
 
   IRB#:11- 183 A  (2) 
29 
Amended: 20 -JAN -2016 
 b. General Medical Exclusions  
Subjects meeting any of the following criteria are ineligible  for study entry:   
 
• Inability to comply with study and/or follow -up procedures  
• Life expectancy of less than 3 months  
• Current, recent (within [ADDRESS_239590] infusion of this study), or planned 
participation in an experimental drug study other than a Genentech- sponsored 
bevacizumab cancer study  
• Active second malignancy, other than superficial basal cell and superficial 
squamous (skin) cell, or carcinoma in situ of the cervix within last five years  
• History of other malignancies, except for ot her solid tumors curatively treated 
with no evidence of disease for > 3 years prior to enrollment.  
• Known infection with human immunodeficiency virus (HIV).  
c. Bevacizumab -Specific Exclusions  
• Uncontrolled hypertension (sBP >150 mmHg and/or diastol ic BP >  100 mmHg, 
found on two consecutive measurements separated by a one week period of time despi[INVESTIGATOR_200911]).  
• Prior history of hypertensive crisis or hypertensive encephalopathy . 
• [LOCATION_001] Heart Association (NYHA) Grade II or greater congestive heart failure 
(see Appendix E) . 
• History of myocardial infarction or unstable angina within 6 months prior to Day -
3. 
• History of stroke or transient ischemic attack within 6 months prior to Day - 3.  
• Known CNS disease, exc ept for treated brain metastases.  
Treated brain metastases are defined as having no evidence of progression or 
hemorrhage after treatment and no ongoing requirement for dexamethasone, as 
ascertained by [CONTACT_47316] (MRI or CT) during the 
screening period.  Anticonvulsants (stable  dose) are allowed.  Treatment for 
brain metastases may include whole brain radiotherapy (WBRT), radiosurgery 
(RS; Gamma Knife, LINAC, or equivalent) or a combination as deemed 
appropriate by [CONTACT_1963].  Patients with CNS metastases treated by 
[CONTACT_47317] 3 months prior to Day -3 
will be excluded.  
• Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or 
recent peripheral arterial thrombosis) within 6 months prior to Day -3. 
• History of hemoptysis ( ≥ 1/2 teaspoon of bright red blood per epi[INVESTIGATOR_1865]) within 
1 month prior to Day - 3. 
• Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation) . 
 
   IRB#:11- 183 A  (2) 
30 
Amended: 20 -JAN -2016 
 • Major surgical procedure, open biopsy, or significant traumatic injury within 
28 days prior to Day - 3 or anticipation of need for major surgical procedure 
during the course of the study . (A major procedure constitutes an invasive 
procedure which requires g eneral anesthetic support, hospi[INVESTIGATOR_059], and 
supportive care such as laparotomy, laminectomy, etc .) 
• Core biopsy or other minor surgical procedure, excluding placement of a vascular 
access device, within 7 days prior to Day 1.  (Minor surgical procedures include 
minimally invasive procedures such as fine needle aspi[INVESTIGATOR_1516], core biopsy, etc  
requiring little if any supportive care excluding lumbar puncture and bone marrow 
aspi[INVESTIGATOR_1516]/biopsy .) 
• History of abdominal fistula or gastrointestinal perforation within 6 months prior to 
Day -3. 
• Serious, non -healing wound, active ulcer, or untreated bone fracture.  
• Thrombolytics or treatment doses of warfarin within 28 days of initiating 
treatment.  Patients who require low dose warfarin for central venous catheter 
patency are allowed to enter if their dose is <  2 mg per day total AND their 
International Normalized Ratio (INR) is ≤ 1.5. 
• Patients requiring treatment doses of heparin for any reason.  The use of heparin flushes for maintenance of central venous catheters is permitted.  
• Patients requiring aspi[INVESTIGATOR_248] >  325 mg per day or non- steroidal anti -inflammatory 
medications known to inhibit platelet function.  Patients taking cyclooxygenase- 2 
inhibitors (COX -2) inhibitors are allowed to enroll.  
• History or clinica l evidence of deep venous thrombosis including pulmonary 
embolus within 6 months of treatment.  
• Patients with proteinuria >  1+ on urine dipstick  or UPC ratio ≥  1.0 at screening .  If 
>1+ proteinuria is detected on surveillance, a 24- hour collection must be 
performed if eligibility is desired.  Patients with a 24- hour urine protein content of 
≤ 500 mg are eligible.  
• Known hypersensitivity to any component of bevacizumab.   
• Pregnancy (positive pregnancy test) or l actation. (An effective  means of 
contraception (men and women) in subjects of child- bearing potential  must be 
used. ) 
6.[ADDRESS_239591] of a 21- day cycle.  Dose modification  
will only occur with administration of the investigational agent, bevacizumab.  
 
The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan  by 3 days (Day -
3) to allow for vascular stabilization prior to initiation of chemotherapy. Refer to Section 7.1.1 for administration guidelines for bevacizumab.  
   IRB#:11- 183 A  (2) 
31 
Amended: [ADDRESS_239592] of cyclophosphamide and topotecan 
administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes   ± 5 
minutes  on Days 0- 4 followed by [CONTACT_148383] 0.75 mg/m2/day IV over 30 minutes   ± 5 
minutes  on Day 0- 4 of every cycle.  The dosing of cyclophosphamide and topotecan will 
be fixed.  
 
 
Dose Escalation Schema  
Dose Level  Cyclophosphamide  
(mg/m2)  
daily x 5 Q 21 days  
Days 0 -4 Topotecan  
(mg/m2)  
daily x 5 Q 21 days  
Days 0 -4 Bevacizumab  
(mg/kg) Q 3 weeks 
Day -3 
-1 250 mg  0.75 mg  - 
1 250 mg  0.75 mg  15 mg  
 
Administratio n of Filgrastim  will begin 24 hours after completion of chemotherapy (Day 
5) at a dose of 5 mcg/kg/dos e subcutaneously until the ANC is ≥ 1,000/μL for 3  
consecutive days or ≥ 10,000/μL for [ADDRESS_239593] been met: 
1) after a  minimum of 21 days since the start of the previous treatment cycle, 2) ANC ≥ 
1000/μL 48 hours after  discontinuation of Filgrastim, and 3) platelet count ≥ 100,000/μL.   
  
In the event of development of the following toxicities  defined as follows, treatment with 
bevacizumab will be withdrawn and therapy resumed with cyclophosphamide and 
topotecan alone:    
 
• If attribution of the event to bevacizumab is felt to be likely or definite  
• For any severe adverse event as outli ned i n Section 7.1.[ADDRESS_239594] guideline (version 1.1) after every 2 
cycles of therapy (6 weeks).  If the response is stable or better, the patient will continue 
on therapy  up to a maximum duration of [ADDRESS_239595]  and second 
cycle of treatment. See Section 8. 6. 
 
6.2 Number of Centers  
This trial will be conducted in the Pediatric Oncology Experimental Therapeutics Investigators ’ 
Consortium (POETIC). Approximately 10 centers in the [LOCATION_002] and Canada will 
participate in this study.  
 
6.3 Number of Subjects  
  
The m aximum  sample size for this study i s anticipated to be a total of 29 patients .  
   IRB#:11- 183 A  (2) 
32 
Amended: 20 -JAN -2016 
  
6.4 Estimated Study Duration 
 
The accrual period is esti mated to be approximately 1 ½ years . The maximum duration of the 
study will be approximately 2 years .  
 
7.0 STUDY MEDICATION   
 
7.1  Bevacizumab Dosage and Formulation  
Bevacizumab is a clear to slightly opalescent, colorless to pale brown, sterile liquid 
concentrate for solution for intravenous (IV) infus ion.  Bevacizumab may be supplied in 
20-mL (400 mg) glass vials containing  16 mL bevacizumab, respectively ( 25 mg/mL) .  
Vials contain bevacizumab with phosphate, trehalose, polysorbate 20, and Sterile Water 
for Injection (SWFI), USP.   Vials contain no preservative and are suitable for single use 
only.  
 
For further details and molecule characterization, see the bevacizumab Investigator 
Brochure.  
7.1.1  Bevacizumab Administration  
Bevacizumab will be diluted in a total volume of 100  mL of 0.9% Sodium Chloride 
Injection, USP.  Administration will be as a continuous IV infusion.  Anaphylaxis 
precautions should be observed during study drug administration.   It is not necessary to 
correct dosing based on ideal weight.  
 
The initial dose will be delivered over 90 ± [ADDRESS_239596] infusion is tolerated 
without infusion- associated adverse events (fever and/or chills), the second infusion may 
be delivered over 60 ± 10 minutes.  If the 60- minute infusion is well tolerated, all 
subsequent infusions may be delivered over 30 ± [ADDRESS_239597] experiences an infusion- associated adverse event, he or she may be 
premedicated for the next study drug infusion; however, the infusion time may not be 
decreased for the subsequent infusion.  If the next i nfusion is well tolerated with 
premedication, the subsequent infusion time may then be decreased by 30± [ADDRESS_239598] experiences an 
infusion- associated adverse event with the 60- minute infusion, all subsequent doses 
should be given over 90 ± [ADDRESS_239599] experiences an 
infusion- associated adverse event with the 30- minute infusion, all subsequent doses 
should be given over 60 ± 10 minutes.  
7.1.2  Bevacizumab Storage  
Upon receipt of the study drug, vials are to be refrigerated at 2° C-8°C  
(36°F-46°F) and should remain refrigerated until just prior to use.  DO NOT FREEZE.  
DO NOT SHAKE.   Vials should be protected from light.  
 
Opened vials must be used within [ADDRESS_239600] be administered within 8 hours.  
   IRB#:11- 183 A  (2) 
33 
Amended: [ADDRESS_239601]. Bevacizumab has a terminal half -life of 21 days; 
therefore, its discontinuation results in slow elimination over several months. There is no 
available antidote for bevacizumab.  
 
Subjects should be assessed clinically for toxicity prior to, during, and after each 
infusion. If unmanageable toxicity occurs because of bevacizumab at any time during the study, treatment with bevacizumab should be discontinued.  
 
Infusion Reaction:  Infusion of bevacizumab should be interrupted for subjects who 
develop dyspnea or clinically significant hypotension. Subjects who experience a NCI CTCAE v. 4 .0 Grade 3 or 4 allergic reaction/hypersensitivity, adult respi[INVESTIGATOR_200912], or bronchospasm (regardless of grade) will be discontinued from 
bevacizumab treatment.  
 
The infusion should be slowed to 50% or less or interrupted for subjects who experience any infusion- associated symptoms not specified above. When the subject’s symptoms 
have completely resolved, the infusion may be continued at no more than 50% of the rate prior to the reaction and increased in 50% increments every 30 minutes if well 
tolerated. Infusions may be restarted at the full rate during the next cy cle.  
 
Adverse events requiring delays or permanent discontinuation of bevacizumab are listed  
below  in Table 1 .  
 
Regardless of the reason for holding study drug treatment, the maximum allowable 
length of treatment interruption is 2 months.  
Table1  
 
Bevacizumab Dose Management Due to Adverse Events 
 
Event  Action to be Taken 
Hypertension 
No dose modifications for grade 1/2 events  
Grade 3  If not controlled to 150/100 mmHg with medication, discontinue 
bevacizumab.  
Grade 4  
(including hypertensive 
encephalopathy)  Discontinue bevacizumab.  
Hemorrhage  
No dose modifications for grade 1/2 non -pulmonary and non- CNS events  
   IRB#:11- 183 A  (2) 
34 
Amended: [ADDRESS_239602] bevacizumab held until all of the following 
criteria  are met:  
• The bleeding has resolved and hemoglobin is stable.  
• There is no bleeding diathesis that would increase the risk 
of therapy.  
• There is no anatomic or pathologic condition that 
significantly increases the risk of hemorrhage recurrence.  
Subjects who experience a repeat Grade [ADDRESS_239603] bevacizumab held until all of the following 
criteria  are met:  
• The bleeding has resolved and hemoglobin is stable.  
• There is no bleeding diathesis that would increase the risk 
of therapy.  
• There is no anatomic or pathologic condition that significantly increases the risk of hemorrhage recurrence.  
 
Grade 2, 3, or 4 
pulmonary or CNS 
hemorrhage  Discontinue bevacizumab . 
Venous Thrombosis  
No dose modifications for grade 1/2 events  
Table 1 
Bevacizumab Dose Management due to Adverse Events (continued)  
 
Grade 3  or 4 Hold study drug treatment.  If the planned duration of full -dose 
anticoagulation is <2 weeks, bevacizumab should be held until the 
full-dose anticoagulation period is over.  If the planned duration of 
full-dose anticoagulation is >2 weeks, bevacizumab may be resumed 
during the period of full -dose anticoagulation if all of the following 
criteria  are met:  
• The s ubject must have an in- range INR (usually between 
2 and 3) if on warfarin; LMWH, warfarin, or other 
anticoagulant  dosing must be stable prior to restarting 
bevacizumab treatment.  
• The subject must not have had a Grade 3 or 4 
hemorrhagic event while on antic oagulation.  
   IRB#:11- 183 A  (2) 
35 
Amended: 20 -JAN -2016 
 Arterial Thromboembolic event  
(New onset, worsening, or unstable angina, myocardial infarction, transient ischemic attack, 
cerebrovascular accident, and any other arterial thromboembolic event)  
 Any grade  Discontinue bevacizumab.  
Congestive Heart Failure (Left ventricular systolic dysfunction)   
No dose modifications for grade 1/2 events  
Grade 3  Hold bevacizumab until resolution to Grade ≤ 1. 
Grade 4  Discontinue bevacizumab.  
Proteinuria  
No dose modifications for grade 1/2 events  
Grade 3  
(UPC>  3.5, urine 
collection > 3.5 g/24 
hr)   
 Hold bevacizumab treatment until ≤ Grade 2, as determined by [CONTACT_200952] ≤ 3.5 or 24 hr collection ≤ 3.5 g  
 
Grade 4 (nephri tic 
syndrome)  Discontinue bevacizumab.  
GI Perforation  
 Discontinue bevacizumab.  
Fistula    
Any grade (TE 
fistula)  Discontinue bevacizumab.  
Grade 4 fistula  Discontinue bevacizumab.  
Bowel Obstruction  
Grade 1   
Continue patient on study for partial obstruction NOT requiring medical 
intervention.  
Table 1  
Bevacizumab Dose Management due to Adverse Events (continued)  
 
Grade 2  Hold bevacizumab for partial obstruction requiring medical intervention.  
Patient may restart upon complete resolution.  
Grade 3/4  Hold bevacizumab for complete obstruction.  If surgery is necessary, patient may restart bevacizumab after full recovery from surgery, and 
at investigator’s discretion.  
Wound dehiscence  
Any grade (requiring 
medical or surgical 
therapy)  Discontinue bevacizumab.  
Reversible Posterior Leukoencephalopathy   
Any grade  
(confirmed by [CONTACT_9268])  Discontinue bevacizumab.  
   IRB#:11- 183 A  (2) 
36 
Amended: 20 -JAN -2016 
 Other Unspecified Bevacizumab -Related Adverse Events 
Grade 3  
Grade 4  Hold bevacizumab until recovery to ≤ Grade [ADDRESS_239604] the 
responsibility to assure the FDA that systems for agent accountability are being 
maintained by [CONTACT_200953].  Investigators may delegate 
responsibility for agent ordering, storage, accountability and preparation to a designee in 
their institutions.  However, the investigator i s ultimately responsible for all agents 
shipped in his/her name.  The intent of agent accountability is to assure that supplied 
agents are only used for patients enrolled on this trial.  Investigational agents will not be 
shipped to a site unless all site and study specific regulatory documents have been 
received by [CONTACT_200954] (DCC). The POETIC DCC will 
notify the site of their activation and provide clearance to order study drug from Fisher Clinical Sciences.  
 
Requests and Shippi[INVESTIGATOR_200913], the site will complete a Drug Shipment 
Authorization form and submit the document to the Fisher Clinical Sciences at the 
address listed below:  
 Fisher Clinical Sciences  
Distribution Study Administration  
[ADDRESS_239605]  
Allentown, PA [ZIP_CODE]  
Phone: 610- 871-8300  
Fax:     610 -871-8590  
E-mail: 
[EMAIL_3946]  
 
The information needed for completion Drug Shipment Authorization form is the POETIC 
protocol number, address, product information and quantity. The POETIC protocol, 
POE10 -01, is included on the form.  Investigational agents will only be shipped to the 
investigator’s designated shippi[INVESTIGATOR_13386].  All changes to the shippi[INVESTIGATOR_200914].   
 
Requests for investigational agents for new subjects should be submitted the day of 
registration and no less than 3 business days prior to the start of treatment.  Requests 
for s ubsequent cycles should be made a minimum of 1 week prior to treatment.  
Telephone requests will not be accepted.  
 Investigational agents will only be shipped to the investigator’s designated shippi[INVESTIGATOR_200915].  All changes to the shippi[INVESTIGATOR_200916] i n writing and signed by [CONTACT_42038].  
 
 
   IRB#:11- 183 A  (2) 
37 
Amended: [ADDRESS_239606] agent(s), 
lot numbers, and quantity were received in adequate shippi[INVESTIGATOR_19944]. Once verified 
the Packing Slip must b e completed, signed and returned to Fisher Clinical Sciences to 
the following contact [CONTACT_200955]: AOR Administrator, FAX# 610- 871-0775. If there are 
problems with the shipment, the Site must notify the AOR Administrator immediately.   
 
If there are any additi onal problems contact:  
 [CONTACT_200956] J. Rieker  
Distribution Project Manager  
Thermo Fisher Scientific (Fisher Clinical Sciences)  
[ADDRESS_239607]  
Breinigsville, PA [ZIP_CODE] Phone: 484- 538-2139     
Fax:     610 -871-0711  
[EMAIL_3947]  
 
7.1.[ADDRESS_239608] at the site will be responsible for handling study drug, preparation 
of the appropriate dose to be administered, and completion of associated documentary 
paperwork. Documentation (receipt, transfer, dispensing, or return) will be maintained on 
the NCI Investigational Dr ug Accountability Record (DAR) .  Alternative accountability 
records may be provided to meet study specific requirements (example –  oral 
medication involving return of meds by [CONTACT_4676]) beyond the DAR form’s capability. A 
copy of the appropriate accountability record will be sent with the investigational agent.  
 
A DAR must be maintained at each location an agent is stored (example –  main 
pharmacy, satellite, etc). A separate DAR will be maintained for each protocol. Protocols 
using more than one supplied agent or more than one strength or formulation of the same agent, each agent, strength, and formulation will be stored separately and a 
separate DAR maintained. Proper completion of the DAR is mandatory, failure to 
complete all fields as required may prevent future shipments until it is determined 
appropriate accountability can be maintained. Each time a dose is prepared for a patient, 
the following information must be recorded: the patient’s initial s, the patient’s study 
number, the total dose prepared, the number of vials of drug product and diluent used, the number of the lot from which the dose was prepared, and the initials of the person 
preparing the dose. Audit of the DAR will be  conducted at t he end of the study and more 
often if needed.  All investigational agents will be stored as per manufacturer 
recommendations in a secure location away from commercial drug stock that is only 
accessible to authorized personnel.  Each agent is to be stored and accounted for 
separately by [CONTACT_990].  
 Investigational agents requiring storage in refrigerator or freezer must be stored within 
the temperature range required by [CONTACT_200957].  The agents must be 
stored separately by [CONTACT_200958]/freezer. No food products may be stored within the refrigerator/freezer.  A thermometer or monitoring device must be 
utilized to monitor and record temperatures on a log posted on the equipment at a 
minimum of once daily.  Out of range tempe ratures must be documented with reason for 
situation and actions taken to correct.   
 
   IRB#:11- 183 A  (2) 
38 
Amended: [ADDRESS_239609] is present, required testing 
completed, and the treating physician’s orders are received.  The investigator will 
administer the agent only to subjects registered to the study and under the inves tigator’s 
personal supervision or under the supervision of a sub- investigator responsible to the 
investigator . 
 
In addition to maintaining records of drug dispensation, an appropriate drug preparation 
log should also be maintained to document how the study  drug solution was prepared. 
Calculations performed for preparation of the drug should be clearly recorded. If the sit e 
does not have such logs, Genentech  will provide them. These logs are to be maintained 
by [CONTACT_200959] a representative of the Sponsor.  
 
7.1.[ADDRESS_239610] practice at each study center. Destruction of such supplies will 
be documented, and a representative of the Sponsor will verify disposition records. No 
other utiliza tion of bevacizumab study drug solution intended for use in this study is 
authoriz ed by [CONTACT_1034]. The Principal  Investigator [INVESTIGATOR_022]/her designee will be 
responsible for the appropriate handling and disposition of residual study drug.  
 
7.1.[ADDRESS_239611]’s appointment must be changed.  
 
Every effort should be made to minimize the amount of agent ordered and returned 
unused.  Unused agents will either be returned or destroyed on- site as directed by [CONTACT_200960]; agent is outdated, damaged or 
unfit for use.  Opened or partially used vials/bottles are not to be returned unless 
specifically requested otherwise in the protocol.  Broken vials are to be destroyed at the 
site, not returned.  
 
If return of investigational agent is not required, the agent will be treated as 
chemotherapy or biological hazardous waste as appropriat e and disposed of in 
accordance to the policies for hazardous waste management at the Site.   
 For agents destroyed on- site, the DAR must be completed and faxed to the POETIC 
DCC.  If the investigational agent is returned, the completed DAR must accompany the agent.   
 
Sites must maintain copi[INVESTIGATOR_200917], Packing Slips, and DARs 
on site, available for monitoring and auditing until final closure of the study.  After final 
closure of the study, forms may be stored off site as per the policy of the site.  
   IRB#:11- 183 A  (2) 
39 
Amended: 20 -JAN -2016 
  
7.2 Protocol Specified Chemotherapy  
 
7.2.1  Cyclophosphamide (Cytoxan) NSC #[ZIP_CODE]  
 
[IP_ADDRESS] Source and Pharmacology:  
Cyclophosphamide is an alkylating agent related to nitrogen mustard. 
Cyclophosphamide is inactive until it is metabolized by P -450 isoenzymes (CYP2B6, 
CYP2C9 and CYP3A4) in the liver to active compounds. The initial product is 4-
hydroxycyclophosphamide (4- HC) which is in equilibrium with aldophosphamide which 
spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard, which is an active bifunctional alkylating species, is 10 times more potent in 
vitro than is 4 -HC and has been shown to produce interstrand DNA cross -linking 
analogous to those produced by [CONTACT_200961]. Approximately 70% of a dose of 
cyclophosphamide is excreted in the urine as the inactive carboxyphosphamide and 5 -
25% as unchanged drug. Cyclophosphamide is well absorbed orally with a bioavailability greater than 75%. The plasma half -life ranges from 4.1 -16 hours after I V administration 
and 1.3 -6.8 hours after oral administration.  
 
[IP_ADDRESS] Formulation:  
Cyclophosphamide for Injection is available as powder for injection or lyophilized powder for injection in 500 mg, 1 gm and 2 gm vials. The powder for injection contains 82 mg 
sodium bicarbonate/100 mg cyclophosphamide and the lyophilized powder for injection contains 75 mg mannitol/100 mg cyclophosphamide.  
 
[IP_ADDRESS] Storage:  
Storage at or below 25ºC (77ºF) is recommended. The product will withstand brief 
exposures to temperatures up to 30º C (86ºF).  
 
[IP_ADDRESS] Reconstitution:  
Cyclophosphamide for Injection: Reconstitute with sterile water or Bacteriostatic water 
for injection (paraben preserved only) to a concentration of 20 mg/ml. If administered as 
undiluted drug at the 20 mg/ml concentration, reconstitute with NS only to avoid a 
hypotonic solution. Cyclophosphamide may be further diluted in dextrose or saline 
containing solutions for IV use.  
 
[IP_ADDRESS] Stability:  
Reconstituted solution with preservative is stable for 24 hours at room temperature, or 6 
days if refrigerated. Solution reconstituted without preservative should be discarded after 
6 hours.  
 
[IP_ADDRESS]  Administration:  
In this study, cyclophosphamide will be administered intrav enously over a 30 minute 
period + 5 minutes on 5 consecutive days.  
 
 
   IRB#:11- 183 A  (2) 
40 
Amended: 20 -JAN -2016 
 7.2.1 .7 Supplier : 
Commercially available from various manufacturers. See package insert for further 
information 
 7.2.1. 8 Safety Profile:  
 
Likely  Less Likely  Rare but Serious  
• Loss of appetite  
• Nausea 
• Vomiting  
• Fewer white blood cells in 
the blood.  
o A low number of white 
blood cells may make 
it easier to get 
infections.  
• Hair loss  
• Decreased ability of the 
body to fight infection  
• Absence or decrease in 
the number of sperm 
which may be temporary 
or permanent which may 
decrease t he ability to 
have children 
 • Abnormal hormone 
function which may lower 
the level of salt in the 
blood 
• Abdominal pain 
• Diarrhea 
• Fewer red blood cells and platelets in the blood  
o  A low number of red 
blood cells may make 
you feel tired and 
weak.  
o A low number of 
platelets may cause 
you to bruise and 
bleed more easily.  
• Bleeding and 
inflammation of the 
urinary bladder  
• Absence or decrease 
monthly periods which 
may be temporary or 
permanent and which 
may decrease the ability 
to have children  
• Temporary blurred vision  
• Nasal stuffiness at time of 
IV infusions  
• Skin rash  
• Darkening of areas of the 
skin and finger nails  
• Slow healing of wounds  
•  Infections  
• Metallic taste in mouth  • Heart muscle damage 
which may occur with very high doses and 
which may be fatal  
• Abnormal heart rhythms  
• Damage and scarring of 
lung tissue which may 
make you short of breath  
• A new cancer or 
leukemia resulting from 
this treatment.  
• Damage or scarring of urinary bladder tissue  
• Severe allergic reaction 
which can be life 
threatening with shortness of breath, low 
blood pressure, rapid 
heart rate chills and fever  
• Infertility which is the inability to have children  
 
 
  
7.2.2  Topotecan, NSC #609699, IND #[ZIP_CODE]  
 
[IP_ADDRESS] Source and Pharmacology:  
Topotecan is a semisynthetic analogue of camptothecin, an alkaloid derived from the 
camptothecin tree which grows widely throughout Asia. The drug is a specific 
   IRB#:11- 183 A  (2) 
41 
Amended: 20 -JAN -2016 
 Topoisomerase -I inhibitor. Topotecan interferes with the repair activity of topoisomerase 
I by [CONTACT_200962] a covalently bonded DNA -Topoi somerase I complex. 
Thus, the 5’ -phosphoryl terminus of the enzyme catalyzed single strand DNA break 
remains bound to the tyrosine of the enzyme thereby [CONTACT_200963]. The 
drug exists as two species in equilibrium in aqueous solutions. One i s a more active 
closed- ring lactone and the other a less active open ring form. Acidic conditions favor the 
closed ring lactone form while basic and physiologic pH  favors the open ring form. In 
human plasma the lactone form is about 21% bound to plasma protein. The drug is 
excreted 39% in urine and the remainder in the stool, the latter is presumably via biliary 
excretion. In rats, over 90% of the radioactivity from [14C]topotecan was recovered in 
stool and urine in the first 96 hours. The half life for the lactone form is 180 minutes.  
 
[IP_ADDRESS] Formulation : 
Topotecan is supplied as a lyophilized, light yellow powder in vials containing 4 mg 
Topotecan AS (as the base) and 48 mg mannitol and 20 mg tartaric acid, NF. The pH is 
adjusted to 3.0. It has a reverse magenta label for identification purposes.  
 
[IP_ADDRESS] Storage:  
Unreconstituted vials are stored at room temperature, 15º -30ºC (59º -86ºF).  
 
[IP_ADDRESS] Reconstitution:  
The contents of each 4 mg vial will be reconstituted with 4 m L Sterile Water for Injection, 
USP, yielding a 1 mg/m L solution of Topotecan AS. The vial can also be reconstituted 
with Bacteriostatic Water for Injection, USP.  
 
[IP_ADDRESS] Stability:  
The vials reconstituted with Sterile Water for Injection, USP, contain no   antibacterial 
preservative and must be used within 8 hours . Those reconstituted with Bacteriostatic 
Water for Injection, USP, are stable for 21 days when stored in the refrigerator (2 -8ºC).  
 
The reconstituted solution will be further diluted to concentrations of 10 mcg/m L to 500 
mcg/m L in Dextrose 5% in Water, Normal Saline, or Bacteriostatic Water for Injection, 
USP. Solutions for infusion in glass or plastic bags are stable at room temperature for 24 
hours if reconstituted with Dextrose 5% in W ater or Normal Saline and are stable for [ADDRESS_239612] been described. The drug is stable in IV solutions as stated 
above.  
 
[IP_ADDRESS] Administration:  
In this s tudy, topotecan will be administered intravenously over a 30- minute  +/- 5 
minutes  on five consecutive days. The appropriate amount of drug should be diluted in 
D5W yielding a final volume of 25 m L. 
 
[IP_ADDRESS] Supplier : 
Commercially available from various manufacturers. See package insert for further 
information . 
 
   IRB#:11- 183 A  (2) 
42 
Amended: 20 -JAN -2016 
 7.2.2. 8 Safety Profile : 
 
Likely  Less Likely  Rare But Serious  
• Diarrhea  
• Nausea 
• Vomiting  
• Constipation 
• Fewer white blood cells, red 
blood cells and platelets in 
the blood.  
• A low number of white blood cells can make it 
easier to get infections  
• A low number of red blood cells can make you feel 
tired and weak  
• A low number of platelets causes you to bruise and 
bleed more easily  
• Fever including fever with a 
low white blood cell count 
which could indicate 
infection and may require 
hospi[INVESTIGATOR_59469]  
• Pain which may be in your 
abdomen, back or bones  
• A feeling of weakness 
and/or tiredness  
• Temporary hair loss  • Loss of appetite  
• Elevation in the blood of certain 
enzymes or bili rubin found in the 
liver which could indicate liver irritation or damage  
• Headache 
• Rash, hives, itching or a red 
bumpy rash  
• A mild lowering of the blood pressure which usually does not 
require treatment  
• Inflammation and/or sores in the 
mouth, throat and/or esophagus  
• An infection in the blood which will require admission to the 
hospi[INVESTIGATOR_200918]  
• Numbness and tingling in the 
fingers and toes  
• Small amount of blood and/or 
protein in the urine or an 
elevation in blood creatinine 
which may in dicate mild kidney 
damage  
• Shortness of breath  
• Muscle or joint aches and pains  
• Chest pain  
• Shaking chills  • Severe allergic reaction 
which can be life 
threatening with shortness 
of breath, low blood 
pressure and a rapid heart 
rate 
• Severe allergic reaction 
which can be life 
threatening with rapid 
build -up of fluid under the 
skin, in the lining of the 
intestine and possibly in 
the throat or swelling of the 
tongue which could make it 
difficult to breath.  
• Bleeding into the tumor 
which may cause damage 
depending  on the location 
of the tumor.  
 
 
 
 
 
 
 
7.3 Concomitant Medications 
Low-dose aspi[INVESTIGATOR_248] ( ≤ 325 mg/d) may be continued in subjects at higher risk for arterial 
thromboembolic disease. Subjects developi[INVESTIGATOR_200919] 1, 
Bevacizumab Dose Manag ement Due To Adverse Events.  
 
All concomitant medications administered within 14 days prior to and during the active 
study period are to be reported on the appropriate case report forms for each patient.  
 
7.3.1   Prior Treatment:  
Reasonable efforts will be made to collect information on all prior cancer treatments 
received by [CONTACT_102] (chemotherapy, radiotherapy, immunotherapy, biologics, etc.). 
The information must be recorded in the patient’s medical chart and on the patient’s 
CRF .  
 
All concomitant medications will be recorded on the appropriate case report forms.  
   IRB#:11- 183 A  (2) 
43 
Amended: 20 -JAN -2016 
  
7.3.2  Permitted Treatment:  
All routine and appropriate supportive care will be provided during this study, as clinically 
indicated, and in accordance with the standard of care practices. Clinical judgment 
should be utilized in the treatment of any adverse event experienced by [CONTACT_102].  
 
Patients should receive ful l supportive care, including hematopoietic growth factors, 
transfusion of blood and blood products, aspi[INVESTIGATOR_248], antibiotics, anti -emetics, as clinically 
appropriate .  Pre-medication (anti -emetics, hydration, antihistamines, etc.) should be 
administered according to institutional standards.  Pneumocystis carinii prophylaxis is 
strongly recommended.  
 
Anti-platelet therapy (e.g. < 325 mg/day aspi[INVESTIGATOR_248]) should be considered f or treatment of 
patients at high risk of developi[INVESTIGATOR_200920]. Low -dose aspi[INVESTIGATOR_248] (≤ 325 mg/d) may be continued in subjects at higher 
risk for arterial thromboembolic disease and are receiving aspi[INVESTIGATOR_200921]. Subjects developi[INVESTIGATOR_200922] 1, Bevacizumab Dose 
Management Due To Adverse Events.  
 Patients may continue or be placed on oral contraceptives or hormone- replacement 
therapy as clinically indicated.  
 
Patients who experience infusion- associated symptoms may be treated symptomatically 
with acetaminophen, diphenhydramine, ranitidine, or other medications as clinically 
indicated.  
 Patient s with indwelling venous catheters may receive prophylaxis against catheter 
thrombosis in accordance with the local standard of care. Because bevacizumab has a 
half-life of approximately 21 days, elective major surgery with the exception of bone 
marrow biopsies should be delayed whenever possible. No data are available to define a safe interval. Re- initiation of bevacizumab following surgery requires documented 
approval from the Principal Investigator [INVESTIGATOR_80336] . 
 
Other medications considered necessary for  the patient’s safety and well -being may be 
given at the discretion of the investigator.  
 
Information on all concomitant medications, blood products administered, as well as 
interventions occurring during the study period must be recorded on the patient’s CRF.  
 
8.[ADDRESS_239613] of care. The informed consent process should 
be documented in the patient’s chart.  
 
   IRB#:11- 183 A  (2) 
44 
Amended: 20 -JAN -2016 
 The following procedures or evaluations will be performed within 7 days prior to 
treatment  with the exception of screening radiologic studies appropriate for the disease 
which will be performed within 14 days of the star t of treatment:  
• Complete medical and surgical history, including demographic data  
• Prior cancer history (including all prior therapy)  
• Complete physical examination 
• Vital Signs (temperature, heart rate, blood pressure and respi[INVESTIGATOR_697])  
• Lansky or Karnofsky performance status  
• Height and weight  
• Neurologic examination in patients with CNS tumors only  
• Laboratory studies  
o CBC (WBC with differential, hemoglobin, hematocrit, and platelets)  
o Serum chemistries ( albumin, sodium, potassium, chloride, bicarbonat e, 
BUN, creatinine, glucose, calcium, total bilirubin,  total protein,  AST, ALT, 
alkaline phosphatase,  phosphorus , and LDH)  
o Serum pregnancy test (for all females of childbearing potential)  as per 
institutional guidelines  
o INR  
o Urine protein: creatinine ratio or urine dipstick (and 24 hour collection if  
indicated)  
• Radiologic studies appropriate for disease assessment (CT, MRI, MIBG, etc.)   
• EKG, echocardiogram, MUGA  (as indicated)  
• CSF cell count and cytology if appropriate for disease assessment  
• Bone mar row aspi[INVESTIGATOR_1516](s) or biopsy if appropriate for disease assessment  
• To determine the impact of bevacizumab on growth and development in children. Baseline assessment of growth and development will consist of bone age films 
(left hand) and measurement of soma tomedin C levels at baseline and at 
designated times during treatment.  The evaluation will be conducted in all 
patients except for females who are post menarche or males who are Tanner 
Stage V.  
• Monitoring of protocol specified adverse events  
• Recording of concomitant medications  
 
8.2 Evaluations During Treatment  
The following procedures or evaluations will be performed weekly during treatment 
except where designated in Table 2:  Required Observations:  
   IRB#:11- 183 A  (2) 
45 
Amended: 20 -JAN -2016 
 • Complete medical and surgical history, including demographic data  
• Complete physical examination 
• Vital Signs (temperature, heart rate, blood pressure and respi[INVESTIGATOR_2842]). Blood 
pressure monitoring will be performed weekly.  
• Lansky or Karnofsky performance status  
• Height and weight  (to be collected prior to each c ycle of treatment)  
• Neurologi c examination every cycle as clinically indicated in patients with non-
CNS tumors.  
• Laboratory studies  
o CBC (WBC with differential, hemoglobin, hematocrit, and platelets)  
o Serum chemistries ( albumin, sodium, potassium, chloride, bi carbonate, 
BUN, creatinine, glucose, calcium,  total bilirubin  ,total protein,  AST, ALT, 
alkaline phosphat ase, phosphorus , and LDH)  
o Serum pregnancy test  before each cycle (for females of childbearing 
potential  only) 
o INR (for patients on warfarin only)  
o Urine protein:  creatinine ratio or urine dipstick (and 24 hour collection if  
indicated) if indicated but otherwise every other dose. Screening urine 
protein cannot substitute for the day [ADDRESS_239614] is to see if there is a change from baseline, after bevacizumab has 
been given.  
• Radiologic studies appropriate for disease assessment ( CT, MRI, MIBG, etc.) 
after every 2 cycles of therapy.  
• EKG, echocardiogram, MUGA  (as indicated)  
• Monitoring of protocol specified adverse events  
• Recording of concomitant medications  
• To determine the impact of bevacizumab on growth and development in children. 
Baseline assessment of growth and development will consist of bone age films 
(left hand ) and measurement of somatomedin C levels at baseline,  [ADDRESS_239615] -Treatment Evaluations / Off Study  
The following procedures or evaluations will be performed at the completion of study 
participation:  
• Complete medical and surgical history, including demographic data  
   IRB#:11- 183 A  (2) 
46 
Amended: 20 -JAN -2016 
 • Complete physical examination 
• Vital Signs (temperature, heart rate, blood pressure and respi[INVESTIGATOR_697])  
• Lansky or Karnofsky performance status  
• Height and weight  
• Neurologic examination for patients with CNS tumors only  
• Laboratory studies  
o CBC (WBC with differential, hemoglobin, hematocrit, and platelets)  
o Serum chemistries (albumin, sodium, potassium, chloride, bicarbonate, 
BUN, creatinine, glucose, calcium, phosphorus, total bilirubin ,total 
protein,  AST, ALT, alkaline phosphate , phosphorus , and LDH)  
o INR (for patients on warfarin)  
o Urine protein: creatinine ratio or urine dipstick (and 24 hour collection if 
indicated)  
• Radiologic studies appropriate for disease assessment (CT, MRI, MIBG, etc.)  
• EKG, echocardiogram, MUGA  (as indicated)  
• Bone aspi[INVESTIGATOR_1516](s) or biopsy if appropriate for disease assessment  
• Monitoring of protocol specified adverse events  
• Recording of concomitant medications  
 
8.4 Study Termination Visit  
A study termination visit should be scheduled for  ~30 days  (28–42 days) after th e 
decision to discontinue study participation. The following evaluations and procedures will 
be performed at this visit:  
• Complete medical and surgical history, including demographic data  
• Complete physical examination 
• Vital Signs (temperature, heart rate, blood pressure and respi[INVESTIGATOR_697])  
• Lansky or Karnofsky performance status  
• Height and weight  
• Monitoring of protocol specified adverse events  
Recording of concomitant medications  
8.5 Overall Survival (OS ) and Time To Progression (TTP)  
Patients who complete or discontinue treatment will be followed for overall survival for up 
to 5 years and/or  to the time of progression. This information will be requested by [CONTACT_200964]/ POETIC Data and Coordinating Center via Email/Phone  
annually. Completion of  case report forms is not required .  
   IRB#:11- 183 A  (2) 
47 
Amended: 20 -JAN -2016 
 TABLE 2 : REQUIRED OBSERVATIONS  
     
Pre- 
Stu
dy  
Wk 
1  
Wk 
2  
Wk 
3  
Wk 
4  
Wk 
5  
Wk 
6  
Wk 
7  
Wk 
8  
Wk 
9  
Wk 
10  
Wk 
11  
Wk 
12  
Off 
Study Study 
Termination 
Visit  
Bevacizumaba  
  
X  
   
X  
  
  
X  
  
  
X  
  
  
  
Cyclophosphamide b  
  
X  
   
X  
  
  
X  
  
  
X  
  
  
  
Topotecanb  X  
  X  
  
 X  
  
 X  
  
  
  
 
Informed consent   
X  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Demographics   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X X 
Medical history   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X X 
Concurrent meds   
X  
X--------------------------------------------------------------------------------------------- X X X 
 
Physical exam   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X X 
 
Vital signs ( temp, HR, RR  esp. BP)   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X X 
 
Height /Weight   
X  
X  
  
  
X  
  
  
X  
  
  
X  
  
  
X X 
 
Performance Status   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X X 
 
CBC w/diff, platelets   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
INR ( For all weeks except 
baseline, collect only for Warfarin 
patient)   
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
Serum chemistryc  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
X  
 
EKG, ECHO, MUGA  
(as indicated)                
 
 
CSF ( as indicated )   
X  
  
  
  
  
  
  
  
  
  
  
  
  
  
B-HCG   
Xd  
  
  
  
Xd  
  
  
Xd  
  
  
Xd  
  
  
  
 
Adverse event evaluation   
X  
X--------------------------------------------------------------------------------------------- X X X 
 
 
Tumor measurements   
 
X  
Tumor measurements are repeated every ≥  4 and < 6 weeks.  Documentation 
(radiologic) must be provided for patients removed from study for progressive 
disease.   
Xe  
 
Radiologic evaluation   
X  
Radiologic measurements should be performed every ≥ 4 and < 6 weeks.  Xe  
Pharmacokinetics   Xf  X X X X X         
Blood for angiogenic profile  
and serum angiogenic  
biomarkers   Xg               
Somatomedin C  Xi             X  
Bone age films  Xi             X  
 
Blood for  Metabolic Signature  
[CONTACT_201005]  X X  
  
  
  
  
  
  
  
  
  
  
 
Urine protein:  creatinine ratio or 
dipstick   
X  
X  
  
  
  
  
  
X  
  
  
  
  
X  
X  
   IRB#:11- 183 A  (2) 
48 
Amended: 20 -JAN -2016 
 a:    Bevaci zumab :  Administered on Day -3 of every 21 day cycle  
b:   Cyclophosphamide/Topo tecan:  Administered on Days 0-  4 of every 21 day cycle  
c:   Albumin, alkaline phosphatase, total bilirubin, bicarbonate, BUN, calcium, chloride, creatinine, glucose, LDH, phosphorus, potassium,     
      total protein, SGOT [AST], SGPT [ALT], sodium.  
d:   Serum pregnancy test  will be preformed at the beginning of each cycle  (Females of childbearing potential).  
e:   Off-study evaluation.   
f:    Pharmacokinetic Analysis: Samples will be collected pre and post treatment . See section 8. 7.1 for schedule.   
g:   Angiogenic Profile and Serum Biomarkers: Day -3 ( prior to administration of bevacizumab), Day 0 (prior to administration of   
      cyclophosphamide), Day 7 and Day 18 (prior to the next scheduled dose of bevacizumab) . 
h:   NMR analysis: Day -3 (prior to administration of bevacizumab), Day 0 (prior to administration of cyclophosphamide), and Day [ADDRESS_239616] cycle of therapy  . 
i:    Bone age films and somatomedin C will be obtained at base line, every [ADDRESS_239617] week.  In the event of treatment delay, 
laboratory studies will be performed at additional time- points as needed for good patient 
care. Radiographic assessments will be performed after every 2 cycles of therapy.  
 8.6    Criteri a For Therapeutic Response/Outcome Assessment  
Patients with measurable disease will be assessed by [CONTACT_48928].  For the 
purposes of this study, all patients with solid tumors will be re- evaluated every 2 cycles 
(≥ 4 and < [ADDRESS_239618] cycle of treatment).  In addition to a baseline 
scan, confirmatory scans will also be obtained 3 weeks following initial documentation of 
an objective response.  If a durable response is documented, response will be re-
assessed every 6 weeks . If treatment is delayed the radiologic imaging will be performed 
after every other cycle (which will result in a longer interval between imaging) .   
 
8.6.[ADDRESS_239619] guideline (version 1.1) proposed by [CONTACT_200965] (RECIST) Committee [ European Journal of Cancer 45:228- 247, 2009 ].  
Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria.  Note:  Lesions are either measurable or non -
measurable using the criteria provided below. The term “evaluable” in reference to 
measurability will not be used because it does not provide additional meaning or 
accuracy.  
 
[IP_ADDRESS]  Measurable Disease 
Measurable lesions are defined as those that can be accurately measured in at least one 
dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques 
(CT, MRI, x -ray) or as ≥  [ADDRESS_239620] be 
recorded in millimeters  (or decimal fractions of centimeters).  
 
 
   IRB#:11- 183 A  (2) 
49 
Amended: 20 -JAN -2016 
 [IP_ADDRESS]  Non- measurable Disease  
All other lesions (or sites of disease), including small lesions (longest diameter <  20 mm 
with conventional techniques or <[ADDRESS_239621] scan), are considered non-
measurable disease.  Bone lesions, leptomeningeal disease, ascites, pleural/pericardial 
effusions, lymphangitis cutis/pulmoni s, inflammatory breast disease, abdominal masses 
(not followed by [CONTACT_462]), and cystic lesions are all non- measurable.  
 [IP_ADDRESS] Target Lesions  
All measurable lesions up to a maximum of five lesions per organ and 10 lesions in total, 
representative of all involved organs, should be identified as target lesions and recorded 
and measured at baseline.  Target lesions should be selected on the basis of their size 
(lesions with the longest diameter) and their suitability for accurate repeated 
measurements (either by [CONTACT_14217]).  A sum of the longest 
diameter (LD) for all target lesions will be calculated and reported as the baseline sum 
LD.  The baseline sum LD will be used as a reference by [CONTACT_200966].  
 
[IP_ADDRESS] Non-target Lesions  
All other lesions (or sites of disease) should be identified as non- target lesions and 
should also be recorded at baseline.  Non- target lesions include measurable lesions that 
exceed the maximum numbers per organ or total of all involved organs as well as non-
measurable lesions.  Measurements of these lesions are not required, but the presence 
or absence of each should be noted throughout follow -up.  
 
[IP_ADDRESS]  Guidelines for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notation using a ruler or 
calipers.  All baseline evaluations should be performed as closely as possible to the 
beginning of treatment and never more than [ADDRESS_239622] of a treatment.  
 
Clinical lesions.  Clinical lesions will only be considered measurable when they are superficial (e.g., skin nodules and palpab le lymph nodes).  In the case of skin lesions, 
documentation by [CONTACT_6775], including a ruler to estimate the size of the lesion, 
is recommended.  
 Conventional CT and MRI.  These techniques should be performed with cuts of [ADDRESS_239623], abdomen, and 
pelvis.  Tumors of the head, neck and extremities usually require specific protocols.  
 
Ultrasound (US).  When the primary endpoint of the study is objective response 
evaluation, US should not be used to measure tumor lesions.  It is, however, a possible 
alternative to clinical measurements of superficial palpable lymph nodes, subcutaneous 
   IRB#:11- 183 A  (2) 
50 
Amended: 20 -JAN -2016 
 lesions, and thyroid nodules.  US might also be useful to confirm the complete 
disappearance of superficial lesions usually assessed by [CONTACT_12148].  
 
Endoscopy, Laparoscopy.  The utilization of these techniques for objective tumor 
evaluation has not yet been fully and widely validated.  Their uses in this specific context require sophisticated equipment and a high level of expertise that may only be ava ilable 
in some centers.  Therefore, the utilization of such techniques for objective tumor 
response should be restricted to validation purposes in reference centers.  However, 
such techniques can be useful to confirm complete pathological response when biopsies 
are obtained.  
 
Cytology, Histology .  These techniques can be used to differentiate between partial 
responses (PR) and complete responses (CR) in rare cases (e.g., residual lesions in 
tumor types such as germ cell tumors, where known residual benign t umors  can 
remain).  
 
Because an effusion may be a side effect of treatment, cytological confirmation of the 
neoplastic origin of any effusion that appears or worsens during treatment (when the 
measurable tumor has met criteria for response or stable disease) is mandatory to 
differentiate between response, stable disease and progressive disease.  
        
8.6.2  Response Criteria  
[IP_ADDRESS]  Evaluation of Target Lesions  
 
Complete Response (CR): Disappearance of all target lesions  
 
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) 
of target lesions, taking as reference the baseline sum LD . 
 
Progressive Disease (PD):  At least a 20% increase in the sum of the LD of target 
lesions, taking as reference the smallest sum LD recorded s ince the treatment started or 
the appearance of one or more new lesions . 
 
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest sum LD since the treatment started . 
 
[IP_ADDRESS]  Evaluation of Non- target Lesions  
 
Complete Response (CR): Disappearance of all non- target lesions and normalization of 
tumor marker level . 
 
Incomplete Response/Persistence of one or more nontarget lesion(s) . 
 
Stable Disease (SD):  or/and maintenance of tumor marker level above the normal limits . 
 
Progressive Disease (PD):  Appearance of one or more new lesions and/or unequivocal 
progression of existing non- target lesions . 
 
   IRB#:11- 183 A  (2) 
51 
Amended: 20 -JAN -2016 
 Although a clear progression of “non -target” lesions only is exceptional, in such 
circumstances the opi[INVESTIGATOR_13387], and the progression 
status should be confirmed at a later time by [CONTACT_463] (or study chair).  
 
If tumor markers are initially above the upper normal limit, they  must normalize for a 
patient to be considered in complete clinical response.  
 8.6.[ADDRESS_239624] response recorded from the start of the treatment until disease progression/recurrence (taking  as reference for progressive disease the 
smallest measurements recorded since the treatment started).  The patient's best 
response assignment will depend on the achievement of both measurement and 
confirmation criteria.  
 
 
Target Lesions   
Non-target Lesions   
New Lesions   
Overall Response 
 
CR  
CR  
No  
CR 
 
CR  
Incomplete 
response/SD   
No  
PR 
 
PR  
Non-PD  
No  
PR 
 
SD  
Non-PD  
No  
SD 
 
PD  
Any  
Yes or No F 
PD 
 
Any  
PD  
Yes or No  
PD 
 
Any  
Any  
Yes  
PD 
 
Note:  Patients with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be classified as having “symptomatic deterioration.”  Every effort should be made to 
document the objective progression, even after discontinuation of treatment.  
 
In some circumstances, it may be difficult to distinguish residual disease from normal 
tissue.  When the evaluation of complete response depends on this determination, it is 
recommended that the residual lesion be investigated (fine needle aspi[INVESTIGATOR_337]/biopsy) 
before confirming the complete response status.  
 
To be assigned a status of PR or CR, changes in tumor measurements must be 
confirmed by [CONTACT_200967] (CT/MRI) [ADDRESS_239625] 
met.  
8.6.4 Confirmatory Measurement/Duration of Response  
 
[IP_ADDRESS]  Confirmation  
To be assigned a status of PR or CR, changes in tumor measurements must be 
confirmed by [CONTACT_200968] 3  weeks after the criteria for response are 
   IRB#:11- 183 A  (2) 
52 
Amended: [ADDRESS_239626] 
once after study entry at a minimum interval of 6 weeks.  
 
[IP_ADDRESS] Duration of Overall Response  
The duration of overall response is measured from the time measurement criteria are 
met for CR or PR (whichever is first recorded) until the first date that recurrent or 
progressive disease is objectively documented (utilizing as reference for progressive 
disease the smallest measurements recorded since the treatment started).  
 The duration of overall CR is measured from the time measurement criteria are first met 
for CR until the first date that recurrent disease is objectively documented.  
 
[IP_ADDRESS] Duration of Stable Disease 
Stable disease is measured from the start of the treatment until the criteria for 
progression are met, utilizing as reference the smallest measurements recorded since 
the treatment started.  
 
8.7 Correlative Studies  
The study will incorporate mandatory exploratory biologic correlative studies to evaluate 
the following:  
 
8.7.[ADDRESS_239627] follow -up visit for response assessment.  
 
Cycle 1 (21 day cycle)  
 Day -3 (Bevacizumab Dose 1): pre and immediate post infusion sample  
Day 7 ± 3 days: Trough  
Day 18 ±3 days: Trough  
 
Cycle 2 (21 day cycle)  
 Day 7 ± 3 days: Trough  
Day 18 ± 3 days: Trough  
 
Trough at follow -up for the initial  response assessment  at [ADDRESS_239628] ion and discarded. 
About 5 mL of blood will be collected in a red top tube at each time point, placed upright  
(30 minutes) and centrifuged 3,000 x g for 10 minutes at 4°C. Serum will be collected 
and stored at – 70°C until analysis .  
   IRB#:11- 183 A  (2) 
53 
Amended: 20 -JAN -2016 
 Samples should be  batched and shipped to the following address:  
 
Aru Narendran, MD, PhD  
University of Calgary  
HRIC Building, Lab 2a34  
[ADDRESS_239629] NW  
Calgary, Alberta T2N 4Z6 
CANADA  
Telephone: ( [PHONE_4326] 
Fax: ([PHONE_4327]  
E-mail: [EMAIL_3948]  
 Bevacizumab concentrations will be determined using an enzyme- linked immunosorbent 
assay (ELISA) established by [CONTACT_8229].  
 
8.7.2 Assessment of Angiogenic Profile  
In order to assess the angiogenic profile in patients enrolled in this study, the following 
analyses will be performed:  
 
Measurement of EPC and HPC  
Blood volumes collected will be based on the patient’s weight as outlined in the 
Procedural Manual  (page 5). Blood will be collected in Cycle 1 only at the following time -
points: Day -3 (prior to bevacizumab therapy), Day 0 (prior to chemotherapy) and 7, and 
prior to next scheduled dose of bevacizumab.  Peripheral blood will be collected in an 
EDTA  tube (purple top tube) and placed on ice. Specimens should be collected Monday 
through Thursday to al low for shippi[INVESTIGATOR_200923].  Blood will be centrifuged to 
collect plasma and then the cellular portion will be diluted and placed on a Ficoll -Opaque 
gradient to obtain the mononuclear cell layer. These cells will be stained for VEGFR1, 
VEGFR2, VEGFR3 along with stem/progenitor markers CD34, CD133 and cKIT.  HPCs 
will be defined as CD34+ VEGFR1+ cells and EPCs will be defined by [CONTACT_200969]2 and 
CD133.  7- AAD staining will be used to assess the number of apoptotic cells. 
Mononuclear cells will also be collect ed and placed in 100 µl lysis solution for RNA 
extraction and quantification of mRNA levels in these circulating mononuclear cells.   
 
Furthermore, we will perform CD34 enrichment by [CONTACT_200970]34 microbeads for flow 
cytometry and to obtain CD34 enriched population for RNA analysis in order to perform 
microarray analysis on CD34+ cells in pediatric lymphoma patients in order to better 
characterize this cell population.   
 We also plan to measure VEGF- A, VEGF -B (signals through VEGFR1 alone), VEGF -C, 
PlGF (signals through VEGFR1 alone), FGF (fibroblast growth factor important in 
fibroblast activation and production of fibronectin the platform for circulating HPCs 
expressing the integr in VLA -4), SDF -1 (stromal derived factor -1 known to mobilize HPCs 
from the  bone marrow), HGF/SC (hepatocyte growth factor/ scatter factor known to be 
elevated in many cancer types and plays a particularly important role in tumor invasion 
and spread) from the platelet -enriched plasma.   The plasma will be obtained after 
centrifuga tion of blood at 2000 rpm for 20 minutes. The collected plasma portion will be 
spun again at 6000 rpm in order to obtain the platelet enriched fraction.  
 
   IRB#:11- 183 A  (2) 
54 
Amended: [ADDRESS_239630] Information for Sample Shipment:  
 David  C. Lyden MD, PhD  
Stavros S. Niarchos  [CONTACT_3348] of Pediatric s, and Cell and Developmental Biology  
Weill Medical College of Cornell University  
[ADDRESS_239631], Box 284 
[LOCATION_001], NY [ZIP_CODE]  
Office : [PHONE_4328]  
Fax:    [PHONE_4329]  
E-mail: [EMAIL_3949]  
8.7.3  Expression of Angiogenesis Associated Serum Biomarkers   
Plasma samples will be collected from patients before and after the initiation of treatment 
at scheduled intervals according to the treatment schema. Samples will be analyzed for 
levels of VEGF, bFGF, Ang- 1, Ang- 2, sFlt -1, sTie -2, and PlGF using commercially 
available ELISA kits (R&D Systems, Minneapolis, MN). Each sample will be assayed in 
triplicate. Technical steps will be carried out according to the instructions supplied by [CONTACT_13989]. Data will be analyzed using GraphPad Prism version 3.00 statistical 
softwa re (GraphPad Software, San Diego, CA). Correlative analysis will be carried out 
with clinical parameters indicated in the protocol such as tumor type, grade, adverse 
events and treatment response.  
 
Five mL of peripheral blood drawn will be collected in EDT A containing tubes (purple top 
tube) in cycle 1 only  at the following time- points:  Day -3 (prior to administration of 
bevacizumab), Day 0 (prior to administration of cyclophosphamide), Day 7 and Day 18 
(prior to the next scheduled dose of bevacizumab)  and centrifuged at 1200 rpm for 
approximately 10 minutes. Transfer collected plasma to Eppendorf tubes (maximum 1 ml 
per tube) and store at - 200C until shipment on dry ice.  Samples can be batched and 
shipped. Please send samples by [CONTACT_200971], T uesday or Wednesday. If 
a sample to be collected on any other day, it can be kept in a - 200C freezer until 
shipment. Please enclose the information for Canada Customs (attached).  
 
If possible, E -mail the shipment information to [EMAIL_3948]  and 
[EMAIL_3942] . 
 
 
 
 
   IRB#:11- 183 A  (2) 
55 
Amended: 20 -JAN -2016 
 The shippi[INVESTIGATOR_200924]:  
 
[CONTACT_201006] of Calgary  
HRIC Building, Lab 2a34  
[ADDRESS_239632] NW  
Calgary, Alberta T2N 4Z6 CANADA  
Telephone: (403)  210-6402  
                   ([PHONE_4327] 
 
8.7.[ADDRESS_239633] been reviewed previously.
70 Briefly, aqueous metabolites will be 
extracted and proteins will be precipi[INVESTIGATOR_153480] a chloroform:methanol system (method of Bligh and Dyer) and an untargeted gas chromatography mass spectrometry (GC -MS) 
analysis will be performed following chemical deriv atization. Multivariate statistical 
methods, namely principal component analysis (PCA) and partial least squares 
discriminant analysis (PLS -DA) will be performed to determine the clustering properties 
of the samples. Database matches will then be done to determine the identities of the 
most significant metabolites. Finally, the identities of the metabolites that change in 
response to treatment will be documented and analyzed.  
           
Tissue for Metabolic NMR Spectroscopy  
 
Optimal sample size is 50 mg of tissue *No formalin or other cold preservatives must be 
used except for the use of liquid nitrogen . Specimens must be harvested in the operating 
room  or biopsy procedure room, with liquid nitrogen on site.  
 
1. Promptly remove the tissue of interest.  
2. Immediately place it in liquid nitrogen.  
3. Store frozen samples at -80 degrees Celsius.  
4. When a sample set is ready to be shipped for analysis, please ship the 
samples via FedEx (overnight) on sufficient dry ice to allow for 48 hours 
of storage.  Ship only on Mondays, Tuesdays , or Wednesdays to avoid 
weekend delays.  See below for shippi[INVESTIGATOR_22026].  
 
Human Whole Blood Collection for Metabolic NMR Spectroscopy  
 
Only heparin- preserved blood can be used for NMR analysis (please, no EDTA and no citrate 
coating).  The heparin tubes have green  tops (sodium heparin)  5 mL whole blood is required  
and will be collected at the following time- points: Day - 3 (prior to bevaci zumab administration), 
Day 0 (prior to cyclophosphamide administration), and Day [ADDRESS_239634] minimum of 5  mL venous blood into a heparin- coated tube.  
2. Shake / vortex well.  
3. Immediately after collection, place the tube on ice for ~10 minutes.  
4. Store samples at -20 or - 80 degrees C elsius . Samples can be batched.  
   IRB#:11- 183 A  (2) 
56 
Amended: 20 -JAN -2016 
 5. When a sample set is ready to be shipped for analysis, please ship the samples 
via FedEx (overnight) on sufficient dry ice to allow for [ADDRESS_239635]. Aru Narendran at the 
telephone number below  and e- mail ( [EMAIL_3948] .) to inform about 
upcoming sample shipment.  Please provide (via email or inside the FedEx box) the 
exact sample study numbers/ identification, including the patient study number, source of sample, date and time of sample collection.  
 
SHIP SAMPLES ONLY ON MONDAYS, TUESDAYS, OR WEDNESDAYS.  
 
Contact [CONTACT_200972] : 
 
[CONTACT_201006] of Calgary  
HRIC Building, Lab 2a34  
[ADDRESS_239636] NW  
Calgary, Alberta T2N 4Z6 
CANADA  
 Telephone: (403) 210 -6402  
                   ([PHONE_4327] 
 
8.7.[ADDRESS_239637] of bone age films  (left  
hand)  and measurement of somatomedin C levels at baseline, [ADDRESS_239638] DISCONTINUATION  
Subjects who meet the following criteria should be discontinued from study treatment:  
• Grade 4 hypertension or Grade 3 hypertension not controlled with medication 
• Nephrotic syndrome  
• Grade 1 pulmonary or CNS hemorrhage  for patients who are receiving full -
dose anticoagulation.  
• Grade ≥ 2 pulmonary or CNS hemorrhage; any Grade 4 hemorrhage  
• Symptomatic Grade 4 venous thromboembolic event (for lung protocols: any 
venous thromboembolic event requiring full dose warfarin or equivalent (i.e., unfractionated or low m olecular weight heparin)  
   IRB#:11- 183 A  (2) 
57 
Amended: 20 -JAN -2016 
 • Any grade arterial thromboembolic event  
• Grade 4 congestive heart failure 
• Gastrointestinal perforation  
• Tracheoesophageal fistula (any grade) or Grade 4 fistula  
•  Bowel obstruction that has not fully recovered despi[INVESTIGATOR_200925] 
• Wound dehiscence requiring medical or surgical intervention 
• Unwillingness or inability of subject to comply with study requirements  
• Determination by [CONTACT_138683]  
• All Gr ade [ADDRESS_239639] an ongoing bevacizumab- related Grade 4 or serious adverse event at 
the time of discontinuation from study treatment will continue to be followed until 
resolution of the event or until the event is considered irreversible (see Section 7.1.3).  
 
10.0 STUDY DISCONTINUATION  
Genentech has the right to terminate this study at any time. Reasons for terminating the 
study may include, but are not limited to, the following:  
• The incidence or severity of adverse events in this or other studies indicate a 
potential health hazard to patients.  
• Patient enrollment is unsatisfactory.  
• Data recording is inaccurate or incomplete.  
 
11.0 STATISTICAL METHODS  
11.1 Determination of Sample Size  
It is anticipated that 1- 2 patients per month will be accrued on this protocol.  Based on 
these estimates, a total of 29 patients will be enrolled on study with patient accrual  
completed in approximately 1 ½ years .   
 
11.2 Stratification of Accrual  
To ensu re that both disease groups are well represented, the accrual will be stratified. 
This measure will allow additional information about the response rates of each 
individual group to be obtained, however the succes s or failure of the combination, CTB, 
will be assessed based upon composite data from  both disease groups combined.  
11.3 Planned Efficacy Evaluations  
11.3.1 Primary Efficacy Variables  
The primary efficacy variables are objective response rate after 2 cycles of treatment  
and duration of response. Patients who experience early progression of disease prior to 
receiving the second cycle of therapy will be considered a treatment failure.  
   IRB#:11- 183 A  (2) 
58 
Amended: 20 -JAN -2016 
 11.3.2 Secondary Efficacy Variables  
The secondary efficacy variables include time to progression The planned length of 
follow -up will be up to 5 years or until disease progression (Please refer to section 8.5  
for data requirements)  
11.3.3 Methods of Analysis 
In previous trials69, conducted in this population, the response rate (CR+ PR) for this 
patient population was approximately 0.30. A minimax Simon 2- stage design that 
differentiates between population response rates of 0.[ADDRESS_239640] 7 patients accrued from each disease group, for a total of 29 patients. 
In this scenario, even if all 5 responses are seen in one disease group, accrual will 
continue; however, this outcome is not likely even if the treatment is effective in only one 
group. (If the response rate in the neuroblastoma group is 55% and EWS 30%, the 
probability of having >
 5/7 responders in NB and 0/7 in EWS is 3%. If NB has 55% 
response rate and EWS has 20%, the probability is 7%.)  At the conclusion of the trial, if 
[ADDRESS_239641] protein levels within patient are equal.  
 
11.4 Analysis of Correlative Studies  
Pharmacokinetic Analysis  
The pharmacokinetic parameters of bevacizumab ( AUC, C max, t1/2) will be calculated 
using  nonlinear mixed effects modeling (NONMEM, GloboMax® LLC, Hanover, MD).    
 
Analysis  of Angiogenic Profile  
Blood samples will be collected at study entry and throughout the course of treatment as 
outlined above.  Categorical data will be compared using Fisher’s exact probability test 
and continuous data will be compared with Student’s tes t if the sample distribution is 
normal or with Mann- Whitney U test if the sample distribution is asymmetrical.  Kaplan-
Meier life -table curves will be constructed to estimate survival free of local -regional and 
distant recurrences and overall survival.  Data on patients who are alive and without 
evidence of disease at the end of five- year study will be considered censored. The 
comparison between survival functions for different strata will be assessed with the log -
rank statistics..  Differences will be cons idered significant when P < 0.05. Using these 
statistical methods, we will compare circulating HPC levels with treatment response and 
disease f ree survival.  C utoff values of ‘positive’ circulating HPC levels will be 
established in order to test these values for discriminating power in predicting disease 
   IRB#:11- 183 A  (2) 
59 
Amended: 20 -JAN -2016 
 outcome.  Once cutoffs are established as it has been in other tumor types,  these values 
will be used to establish correlation with disease outcome.   
 
Analysis of Expression of Angiogenesis Associated Seru m Biomarkers  
Each sample will be assayed in triplicate. Technical steps will be carried out according to 
the instructions supplied by [CONTACT_3455]. The quantity of individual cytokines (pg/ml) found in each sample and control normal plasma (n=20, investigator’s collection) 
will be analyzed as follows. The Wilcoxon signed ranks test or paired t -test will be used 
to compare pre and post treatment protein levels as appropriate. To examine differences between patients and controls, and at various time points with respect to treatment, 
Wilcoxon- Mann Whitney test or Student's t -test will be used.  The Spearman rank 
correlation test will be used to assess whether the levels of the measured cytokines 
correlated with clinical parameters indicated in the protocol  such as tumor type, grade, 
adverse events and treatment response. All analyses will be performed by [CONTACT_200973] 9.1, and, P -values less then .[ADDRESS_239642].   
 
The protocol principal investigator/ POETIC DCC  are required to report to Genentech 
Drug Safety ANY serious treatment emergent adverse event (STEAE) as soon as possible.   
 
A STEAE is any sign, symptom or medical condition that emerges during Bevacizumab 
treatment or during a post -treatment follow -up period that (1) was not present at the start 
of Bevacizumab treatment and it is not a chronic condition that is part of the patient’s 
medical history, OR (2) was present at the start of Bevacizumab treatment or as part of 
the patient’s medical history but worsened in severity and/or frequency during therapy, 
AND that meets any of the following regulatory serious criteria:  
• Results in death  
• Is life -threatening  
• Requires or prolongs inpatient hospi[INVESTIGATOR_059]  
• Is disabling  
• Is a congenital anomaly/birth defect  
• Is medically significant or requires medical or surgical intervention to prevent one 
of the outcomes listed above.  
  
   IRB#:11- 183 A  (2) 
60 
Amended: 20 -JAN -2016 
 The following events will not be considered reportable:  
 
• Grade 3 or 4 Neutropenia for a duration < 7 days  
• Grade 3 or 4 Leukopenia for a duration < 7 days  
• Lymphopenia  
• Grade 3 or 4 Thrombocytopenia for a duration < 7 days  
• Anemia 
 
12.[ADDRESS_239643] administration of study drug, as well as any 
SAEs designated possibly, probably or definitely related to treatment that occur greater 
than 30 days.  
 
The descriptions and grading scales found in the revised NCI Common Terminology 
Criteria for Adverse Events (CTCAE) version 4.[ADDRESS_239644] access to a copy of 
the CTCAE version 4 .0.  A copy of the CTCAE version 4 .0 can be downloaded from the 
CTEP web site ( http://ctep.cancer.gov/reporting/ctc.html ).  
 
The Protocol Chai rman is required to report all adverse events that occur during the 
clinical study starting when the patient signs consent throughout [ADDRESS_239645] be reported  by [CONTACT_101434]/or telephone to the Protocol Chairman,  Data and Coordinating Center at Memorial 
Sloan- Kettering Cancer Center , and local IRB within [ADDRESS_239646] be sent to the 
Protocol Chairman and Data and Coordinating Center within another 3 calendar days, 
using the Serious Adverse Event case report form  and MedWatch 3500a form.  
 Additionally, the Protocol Chairman is responsible for submitting follow -up reports for all 
SAEs regarding the patient’s subsequent course until the SAE has resolved or until the 
patient’s condition stabilizes (in the case of persistent impairment), or the patient dies .   
 
In the event of an adverse event the first concern will be for the safety of the subject.   
 
Investigators are required to report to the DCCANY  serious treatment emergent adverse 
event (STEAE) as soon as possible.  The Protocol Chairman is responsible for reporting 
such STE AEs to Genentech Drug Safety . 
 
 
 
 
 
 
 
 
   IRB#:11- 183 A  (2) 
61 
Amended: [ADDRESS_239647] ug 
 
  
Grade 1   
Grade 2   
Grade 2   
Grade 3   
Grade 3  Grades  
4 & [ADDRESS_239648] dose of study 
treatment require an SAE report as follows:  
• Grade 3 unexpected events with hospi[INVESTIGATOR_318]  
• Grade 4 unexpected events  
• Grade [ADDRESS_239649] include:  
• Grade of event  
• Date of event  
• A brief description of the event  
• Attribution to the  protocol defined drug combination  
• Patient Status  
 
Relationship of any adverse event to  protocol defined drug combination should use the following 
criteria:  
• Definite - The adverse event is clearly related to  the drug combination 
• Probable - The adverse event is likely related to  the drug combination.  
• Possible - The adverse event may be related to  the drug combination.  
• Unlikely - The adverse event is doubtfully related to the drug combination.  
• Unrelated - The adverse event is clearly NOT related to the drug combination.  
 STEAEs must be reported within 24 hours  of the investigator’s knowledge  by [CONTACT_14223] 
e-mail to:  
• Data and Coordinating Center  
• Lead Principal Investigator [INVESTIGATOR_87031]/ Protocol Chairman -  ([CONTACT_201007])  
• Local IRB  
 
STEAE contact [CONTACT_200974]:  
Memorial Sloan Kettering Cancer Center  
Pediatric & Allo Transplant Clinical Trials Office  
[ADDRESS_239650], room 3 -512 
[LOCATION_001], NY [ZIP_CODE]  
Phone: 646- 888-5714/5715 
Fax: 646- 888-5726  
   IRB#:11- 183 A  (2) 
62 
Amended: [ADDRESS_239651] information for the Protocol Principal  Investigator [INVESTIGATOR_200926]:  
Tanya Trippett, MD  
Memorial Sloan- Kettering Cancer Center  
 [ADDRESS_239652] 
 [LOCATION_001], NY [ZIP_CODE]  
 Telephone (212) 639- 8267 
 Fax (212) 717 -3239  
 E-mail [EMAIL_3936]   
 
In the event of an AE, appropriate medical and supportive care will be administered. All    
efforts will be made to minimize the side effects and to support the patient until the 
toxicity resolves.  
 
12.2.1 Reporting of STEAE  to Sponsor  
 
All STEAEs should be recorded on a MedWatch 3500a Form and faxed to:  
 
Data and Coordinating  Center/Principal Investigator  
[INVESTIGATOR_200900], MD  
Fax: 646- 888-5726  
 
Reporting of STEAEs to the sponsor are to be handled by [CONTACT_200975]- Kettering Cancer Center.  The DCC will fax all STEAEs to:  
 
Genentech Drug Safety  Fax: (650) 225- 4682 or (650) 225- 5288  
 
MedWatch 3500a Reporting Guidelines:  
 
In addition to completing appropriate patient demographic and suspect medication 
information, the report should include the following information within the Event 
Description (section 5) of the MedWatch 3500a form:  
 
• Treatment regimen (dosing frequency, combination therapy)  
• Protocol description (and number, if assigned)  
• Description of event, severity, treatment, and outcome, if known  
• Supportive laboratory results and diagnostics  
• Investigator’s assessment of the relationship of the adverse event to each 
investigational product and suspect medication  
 
Follow -up information:   
 
Additional information may be added to a previously submitted report by [CONTACT_51756]:  
• Adding to the original MedWatch 3500a report and submitting it as follow -
up 
• Adding supplemental summary information and submitting it as follow -up 
with the original MedWatch 3500a form  
   IRB#:11- 183 A  (2) 
63 
Amended: 20 -JAN -2016 
 • Summarizing new information and faxing it with a cover letter including 
subject identifiers (i.e. D.O.B. initial, subject number), protocol description 
and number, if assigned, suspect drug, brief adverse event description, 
and notation that additional or follow -up information is being submitted  
(The subject identifiers are impo rtant so that the new information is added 
to the correct initial report)  
 
Occasionally Genentech may contact [CONTACT_15483], clarification, or current status of the subject for whom and adverse event was reported.  
 
Assessing Causality:  
 
Investigators are required to assess whether there is a reasonable possibility that bevacizumab caused or contributed to an adverse event.  The following general 
guidance may be used.  
 Yes: If the temporal relationship of the clinical event to bevacizumab 
administration makes a causal relationship possible, and other drugs, therapeutic 
interventions or underlying conditions do not provide a sufficient explanation for 
the observed event.  
 
No: If the temporal relationship of the clinical event to bevacizumab 
administration makes a causal relationship unlikely, or other drugs, therapeutic 
interventions or underlying conditions provide a sufficient explanation for the 
observed event.  
 
12.[ADDRESS_239653] comply with the following 
safety reporting requirement s:  
 
a. Expedited IND Safety Reports:  
7 Calendar -Day Telephone or Fax Report :   
The Sponsor -Investigator is required to notify the FDA of any fatal or life- threatening 
adverse event that is unexpected and assessed by [CONTACT_200976].  An unexpected adverse event is one that is not 
already described in the Investigator Brochure.  Such reports are to be telephoned or 
faxed to the FDA and Genentech within [ADDRESS_239654] learning of the event.  
Each telephone call or fax transmission (see fax number below) should be directed to 
the FDA new drug review division in the Center for Drug Evaluation and Research or in 
the product review division for the Center for Biologics Evaluation and Research, 
whichever is responsible for the review of the IND.  
 
15 Calendar -Day Written Report :   
The Sponsor -Investigator is also required to notify the FDA and all participating 
investigators, in a written IND Safety Report, of any serious, unexpected AE that is 
considered possibly related to the use of bevacizumab.  An unexpected adverse event is 
one that is not already described in the Investigator Brochure.  
   IRB#:11- 183 A  (2) 
64 
Amended: 20 -JAN -2016 
  
Written IND Safety Reports should include an Analysis of Similar Events in accordance 
with regulation 21 CFR § 312.32.  All safety reports previously filed with the IND 
concerning similar events should be analyzed.  The new report should contain 
comments on the significance of the new event in light of the previous, similar reports.   
 
Written IND safety reports with Analysis of Similar Events are to be submitted to the 
FDA, Genentech Drug Safety, and all participating investigators within [ADDRESS_239655] learning of the event.  The FDA prefers these reports on a MedWatch 3500a 
Form but alternative formats are acceptable (e.g. summary letter).  
 
FDA fax number for IND Safety Reports:  
 1 (800) FDA - [ADDRESS_239656] 
also be faxed to:  
 Genentech Drug Safety  
Fax: (650) 225- 4682 or (650) 225- 5288 
(Please use the safety reporting fax cover sheet attached to this document for your fax transmission)  
 
AND:  
 
Study Coordination Center/Principal Investigator  
[INVESTIGATOR_200900], MD  
Fax: 646- 888-[ADDRESS_239657]:  
 Genentech Drug Safety  
Tel: [PHONE_483]  
         or 
Fax: (650) 225- 4682 or (650) 225- 5288  
(Please use the safety reporting fax cover sheet attached to this document for your fax transmission)  
 
b. IND Annual Reports  
In accordance with the regulation 21 CFR § 312.32, the Sponsor -Investigator shall within 
[ADDRESS_239658] submit a brief report of the 
progress of the investigation.  Please refer to Code of Federal Regulations,  21 CFR § 
312.[ADDRESS_239659] of the elements required for the annual report.  All IND annual reports submitted to the FDA by [CONTACT_1034] -Investigator should be copi[INVESTIGATOR_38269].  
Copi[INVESTIGATOR_200927]:  
  
 
 
   IRB#:11- 183 A  (2) 
65 
Amended: 20 -JAN -2016 
 Genentech, Inc.  
ATTN: Avastin IST Coordinator  
[ADDRESS_239660] , Mailstop 445- A 
South San Francisco, CA [ZIP_CODE]- 4990  
Tel: (650) 225 -7121 (Oncology Hotline)  
 
PLEASE NOTE: Section 12.4 is mandatory if your site has received an IND 
Exemption Letter from the FDA  
 
12.4 Safety Reporting Requirements for IND Exempt Studies  
For Investigator Sponsored IND Exempt Studies , there are some reporting 
requirements for the FDA in accordance with the guidance set forth in 21 CFR 314.80.  
 
Postmarketing 15- Day “Alert Report” : 
The Sponsor -Investigato r is required to notify the FDA of any fatal or life- threatening 
adverse event that is unexpected and assessed by [CONTACT_200976]. An unexpected adverse event is one that is not 
already described in the Investigator Brochure. Such reports are to be submitted to the 
FDA (2 copi[INVESTIGATOR_014]) at the following address: Central Document Room, [ADDRESS_239661], Rockville, MD [ZIP_CODE].  
 
All Postmar keting 15 -Day “Alert Reports” submitted to the FDA by [CONTACT_1034] -
Investigator must also be faxed to: Genentech Drug Safety   
Fax: (650) 225- 4682 or (650) 225- 5288 (Please use the safety reporting fax cover 
sheet attached to this document for your fax transmission)  
 For questions related to safety reporting, contact:  
 [CONTACT_200977]: [PHONE_483]  
         or 
Fax: (650) 225- 4682 or (650) 225- 5288  
(Please use the safety reporting fax cover sheet attached to this document for your fax 
transmission)  
 
13.0 RETENTION OF RECORDS  
U.S. FDA regulations (21 CFR 312.62[c] and the ICH Guidelines for GCP require that records and documents pertaining to the conduct of this study and distribution of the 
bevacizumab including CRFs, consent forms, laboratory test results, documentation of 
adverse events, medication inventory records, and all IRB correspondence must be 
retained by [CONTACT_079] [INVESTIGATOR_25653] 2 years after the investigation is 
completed
. 
14.0 RECRUITMENT PLAN/INFORMED CONSENT  PROCEDURES  
14.[ADDRESS_239662] females or minorities. Informed 
consent will be obtained from the patient, or if they are non-emancipated minors, their 
   IRB#:11- 183 A  (2) 
66 
Amended: 20 -JAN -2016 
 parent or legal guardian. Consent will be obtained by [CONTACT_200978]. Patients will not receive any payment for their participation in this study.  
 
14.2  Patients or their parent/legal guardian will be required to sign an IRB approved 
statement of informed consent indicating the investigational nature of this study , 
indicating their consent to participate.  
 
This consent form meets the requirements of the Code of Federal Regulations and the 
Institutional Review Board/Privacy Board of this Center. The consent form will include 
the following:  
1. The nature and objectives, potential risks and benefits of the intended 
study.  
2. The length of study and the likely follow -up required.  
3. Alternatives to the proposed study. (This will include available standard 
and investigational therapi[INVESTIGATOR_014]. In addition, patients will be offered an 
option of supportive care for therapeutic studies.)  
4. The name [CONTACT_6823](s) responsible for the protocol.  
5. The right of the  participant to accept or refuse study 
interventions/interactions and to withdraw from participation at any time.  
Before any protocol -specific procedures can be carried out, the consenting professional will fully 
explain the aspects of patient privacy concerning research specific information.  In addition to 
signing the IRB Informed Consent, all patients must agree to the Research Authorization 
component of the informed consent form.  
 
14.3 The investigators listed on the cover page and their qualified desi gnees at each 
institution as listed on the FDA 1572 for this study may obtain consent and care for the 
patients according to good clinical practice and protocol guidelines.  
 
14.4 One to three copi[INVESTIGATOR_200928], parent or the patient's legally authorized representative and by [CONTACT_200979], as per institutional guidelines. If institutional guidelines 
mandate that only one original copy is signed, the following sentences will refer to 
photocopi[INVESTIGATOR_200929]. One copy will be given to the patient/parent/legal guardian to 
be retained for their personal records. One copy will be maintained on file at the Data 
and Coordinating Center. The third copy will be confidentially maintained by [CONTACT_200980].  
 
14.[ADDRESS_239663] documenting that informed consent 
was obtained for this study, and that the patient and/or his/her parents, to the degree of 
their understanding, acknowledge and accept  the risk of participation in this study.  
 14.[ADDRESS_239664] be verified by [CONTACT_200981] (or equivalent 
entity) of the participating institution prior to entry on study. A copy of the consent form, 
along with the eligibility checklist, and Health Insurance Portability and Accountability 
Agreement (HIPAA) must be su bmitted to the Clinical Trials Office at the Data and 
Coordinating Center prior to enrollment of any subject on this study. Verification of 
subject enrollment on this study will be sent by [CONTACT_200982].  
   IRB#:11- 183 A  (2) 
67 
Amended: [ADDRESS_239665] to 
enrollment of patients of different races and g enders. It is anticipated that enrollment of 
the current study will follow the same pattern.  
Institution  Number of 
Patients  White  
Non-Hispanic  
(%) Black  
Non-Hispanic  
(%) Hispanic  
(%) Other  
(%) 
MSKCC  147 61.0 19.0 15.0 5.0 
JHMC  77 73.0 21.0 1.0 5.0 
UCS/TCH  204 62.0 0.0 34.0 4.0 
MDACC  146 60.0 5.0 29.0 6.0 
DFCI  250 81.3 4.7 0.5 9.2 
PCH  137 65.7 < 0.[ADDRESS_239666] be centrally registered at the POETIC Data and Coordinating Center  
(DCC) located at  Memorial Sloan- Kettering Cancer Center.  Registrations will be 
handled by [CONTACT_200983] P OETIC DCC.  The contact [CONTACT_200984] (646) 888 -
5714/5715 and the fax number is (646) 888 -5726.  Registrations will occur between 9:00 
am and 5:[ADDRESS_239667] Time (EST), Monday through Friday and will include 
review of the signed consent form, HIPAA research author ization form, eligibility 
checklist, eligibility source documentation and Patient Enrollment form.  The RSA will 
also verify, via a FAX /email  copy, that the written informed consent is obtained and 
dated prior to subject entry on the study.  
   IRB#:11- 183 A  (2) 
68 
Amended: [ADDRESS_239668] the Research Study Assistant (RSA) at the POETIC 
DCC and the Protocol Principal Investigator  [INVESTIGATOR_200930] a slot on the protocol when a 
patient is being considered for a trial. To begin a registration the participating site must fax/email the signed consent form and HIPAA research authorization to the RSA within 
[ADDRESS_239669] be faxed/emailed  to the RSA at MSKCC prior to protocol treatment or any 
research tests.  
 
All research participants are registered through the Protocol Participant Registration 
(PPR) Office at Memorial Sloan- Kettering Cancer Center  by [CONTACT_200985] .  PPR is 
available Monday through Friday from 8:30am - 5:[ADDRESS_239670] be faxed to 
the POETIC DCC and the Research Study Assistant (RSA) at MSKCC will verify 
eligibility and complete the registration with the PPR Office.   
 
Once eligibility has  been established and the participant is registered, the participant will 
be assigned an MSKCC Clinical Research Database (CRDB) number (protocol 
participant  number). This number is unique to the participant and must be written on all 
data and correspondence for the participant. This protocol participant number will be 
relayed back to study staff at the registering site via e- mail and will serve as the 
enrollment confirmation.  
 
The registration procedure is summarized below.  
 
Confirm that the patient has received the Notice of Privacy Practice if local institutional 
requirement .  This must be obtained before the eligibility confirmation and obtaining of 
the research informed consent.  
Confirm eligibility as defined in the section entitled Criteria for Patient/Subject Eligibility.  
 Obtain written informed consent, by [CONTACT_200986] 14.0, 
Recruitment Plan/ Informed Consent Procedures
. 
 
15.2 Randomization  
 
This study does not include randomization. 
 
16.0 DATA  MANAGEMENT ISSUES  
16.1    Data and Coordinating Center (DCC)  
The Research Study Assistant (RSA) at POETIC DCC will be assigned to the study. The 
responsibilities of the RSA include project compliance, data collection, abstraction and entry, data reporting, regulatory monitoring, pr oblems and prioritization.  The Clinical 
Research Coordinator, CRS , is responsible for coordination between the RSA and 
Research Staff at the following member institutions:  Alberta Children’s Hospi[INVESTIGATOR_307], 
Memorial Sloan- Kettering Cancer Center, Phoenix Children’s Hospi[INVESTIGATOR_307], Children’s 
Hospi[INVESTIGATOR_200931] , Children’s Mercy Hospi[INVESTIGATOR_15166], and Pennsylvania State 
University College of Medicine, is necessary in order for a complete process. The CRS 
   IRB#:11- 183 A  (2) 
69 
Amended: [ADDRESS_239671] format and will be provided to each 
participating  institution by [CONTACT_15791]. The participating Site PI [INVESTIGATOR_200932] . The Site PI [INVESTIGATOR_200933] o f the end of a treatment cycle. Required study tools for each protocol including 
correlative studies, vital  signs, drug administration and protocol evaluations will also be 
provided to each participating  institution by [CONTACT_15791]. Case report forms, study tools and 
source documentation are required to be submitted to the DCC one week after the 
completion of each cycle. The data collected for  this study will be entered into a secure 
database by [CONTACT_200987]. Data will be  collected, stored, and monitored 
at an institutional level via the Clinical Research Database (CRDB) system. Data will be 
provided from CRDB to protocol -defined sponsors (CTEP, FDA,  etc.) as required, 
through the Data Management Resource Division, a division of the Office of  Clinical 
Research.  
 
Source documentation will be available to support the computerized patient record and 
must be submitted with the case report forms and required study tools. Case report forms 
will not be cons idered source documentation.  
 
• Variables that will be recorded include the patient's birth date, date of diagnosis, 
date of study entry and histologic diagnosis.  
• The results of the pretreatment and end of therapy evaluations, including the 
extent of disease evaluation (history, physical examination and imaging studies), 
baseline laboratory values, renal and hepatic function, as defined per protocol, 
will be recorded.  
• All study related treatment data and concomitant drugs will be recorded.  
• The presence of  toxicity at baseline, during and for 30 days after administration 
of the investigational agent will be monitored and recorded.  
• The results of the extent of disease evaluation (history, physical examination and 
imaging studies) following each course of tr eatment will be recorded.  
• The patient's disease status and last follow -up will be recorded. If disease 
progresses or recurs, the results of the repeat extent of disease evaluation will be 
recorded.  
 
16.2 Site Research Staff  
Research staff will be assigned at Alberta Children’s Hospi[INVESTIGATOR_307],  Memorial Sloan- Kettering 
Cancer Center, Phoenix Children’s Hospi[INVESTIGATOR_307], Children’s Hospi[INVESTIGATOR_200931],  Children’s 
Mercy Hospi[INVESTIGATOR_15166],  and Pennsylvania State University College of Medicine.  
Their responsibilities will  include project compliance, data collection, abstraction and 
entry, data reporting, regulatory monitoring, problems and prioritization, maintaining file 
documentation of  data for the clinical trial, pharmacokinetic or other biologic correlative 
study coll ection, and analysis as outlined for each patient enrolled on study. They will 
also be responsible for  maintaining a regulatory binder for each protocol. The designated 
research staff will also be responsible for submitting the data on a weekly basis by [CONTACT_200988].  Case report forms and required study tools along with 
   IRB#:11- 183 A  (2) 
70 
Amended: 20 -JAN -2016 
 supporting source documentation should be faxed/emailed or mailed to the address 
below, one week after the completion of each study cycle:  
 
   POETIC Data and Coordinati ng Center  
Memorial Sloan Kettering Cancer Center  
Pediatric & Allo Transplant Clinical Trials Office  
[ADDRESS_239672], Room 3- 512 
[LOCATION_001], NY [ZIP_CODE]  
Phone: 646- 888-5714/5715 
Fax: 646- 888-[ADDRESS_239673] of the study , monitoring of the 
progress of the study, and review of all case report forms from each participating 
institution.   
 
Failure to submit required forms in the timelines requested will result in suspension of 
accrual privileges at a given site until data is updated, and/or withholding of contract 
payments if applicable.   
 
Initial Protocol Submission  
Prior to implementing t he protocol, informed consent form, HIPAA authorization and any 
other information pertaining to participants must be approved by [CONTACT_200989]/PB. 
Prior to implementing this protocol at the participating centers,  approval must be 
obtained from the participating center’s Local IRB of Record.  The following documents 
must be provided to MSKCC before the participating site can be initiated and begin 
enrolling participants:  
• Local IRB of Record approval(s) for the protocol, appendices, informed consent  
      form and HIPAA authorization  
• Local IRB approved consent form  
• Local IRB of Record membership  
• Local IRB of Record’s Federal Wide Assurance number and OHRP Registration  
      number  
• Curriculum vitae and medical license for each investigator and consenting 
      professional  
• Documentation of Human Subject Research Certification and HIPAA training for  
      investigators and key staff members  
• Signed and dated FDA Related Forms 1572/1571 (if applicable)  
• Lab Certifications and Reference Ranges for each lab listed on the 1572  
• Appropriate financial disclosure forms.  
 
Protocol Amendments/Status Changes  
Each change to the protocol must be organized and documented by [CONTACT_200990]. 
After  IRB approval at the lead institution, the POETIC DCC will distribute the amendment 
to the participating institutions, for approval by [CONTACT_200991] 60 days of the 
   IRB#:11- 183 A  (2) 
71 
Amended: [ADDRESS_239674] be submitted at 
each site to the IRB for review and approval  before patients can be enrolled on the study 
and within 60 days of the amendment version date. The amendment number and 
version date will also be displayed on each amendment.  
 
16.4  Additional IRB Correspondence  
Annual re- approval  
Annual continuing review reports from a participating center’s Local IRB of Record must 
be submitted to MSKCC at the time re -approval is granted. The most current approved 
version of  the consent form should also be submitted to MSKCC at that time. Failure to 
submit the reapproval  will result in suspension of accrual privileges.  
 
Deviations and Violations 
If a deviation from the protocol is proposed for a potential or existing participant at a  
participating site, approval from the MSKCC IRB/PB is required prior to the action.  
For all protocol violations, the participating site should report the violation to [CONTACT_201007]  the Director of the POETIC DCC, as soon as possible. [CONTACT_201008] will in turn 
the report of the violation to the MSKCC IRB/PB.  Participating sites should report 
deviations and violations to the Local IRB of Record as they  occur. 
Approvals/acknowledgments from the Local IRB of Record for protocol deviations and 
violations should be submitted to POETIC DCC as received.  
 
Other correspondence  
Participating sites should submit other correspondence to their local IRB of Record 
according to local guidelines, and submit copi[INVESTIGATOR_200934] . 
 
16.[ADDRESS_239675] be provided to the DCC 
to ensure that real -time monitoring can be accomplished. Queries will be generated by 
[CONTACT_200992], and prompt responses are requested back to the 
   IRB#:11- 183 A  (2) 
72 
Amended: 20 -JAN -2016 
 DCC.  Internal audits will be conducted by [CONTACT_15791]. Audits may be accomplished in one 
of two ways:  (1) source documents and research records for selected patients are 
brought from participating  sites to the DCC for audit, or (2) selected patient records may 
be audited on- site at participating  sites. These audits will be performed by [CONTACT_200993]. 
During these audits the following activities will take place:  
• Review regulatory binders for protocol documentation;  
• Ensure that case report forms are source data verified according to the  
       monitoring plan  
• Verify drug accountability is complete and accurate; and  
• Verify compliance to GCPs, ICH guidelines, FDA regulations, and applicable 
      SOPs.  
 
If the sponsor chooses to have an audit at the DCC, then the DCC is responsible for 
having all  source documents, research records, all IRB approval documents, Drug 
Accountability Record Forms, patient registration lists, response assessments scans, x -
rays, etc. available for the audit. Alternatively, an external auditor would be designated 
for this study through a contract  with MSKCC.  
  
16.6  Data and Safety Monitoring  
The Data and Safety Monitoring Committee (DSMC) under the direction of [CONTACT_201009] and Bonnie Edelman, Manager, will be responsible for monitoring the data safety 
of the protocols sponsored by [CONTACT_200994]. The DSMC meets quarterly, and will review data 
from phase I, II, I/II, pi[INVESTIGATOR_200935]- phase trials that are not being monitored by [CONTACT_200995] [ADDRESS_239676].  
 
The Data and Safety Monitoring (DSM) Plans at Memorial Sloan- Ketterin g Cancer 
Center were approved by [CONTACT_30589] 2001. The DSM 
Plans at MSKCC were established and are monitored by [CONTACT_30591].   
The plans address the new policies set forth by [CONTACT_200996] “Policy 
of the National Cancer Institute for Data and Safety Monitoring of Clinical Trials” which can be found at: http://cancertrials.nci.nih.gov/clinicaltrials/conducting/dsm -guidelines
.  
 
During the protocol development and review process, each protocol will be assessed for 
its level of risk and degree of monitoring required. Risk levels are as follows:  
  
Low Risk : Probability of harm or discomfort not greater than daily life or routine 
physical/psychological exams.   
 
Moderate Risk : Intervention commensurate with those inherent in their expected 
medical, social, or education situations. Risks are reasonable in relation to anticipated 
benefits and the importance of knowledge expected to result.   
 
High Risk : Pose greater than minimal risk which may or may not have direct benefit to 
the participant.   
 
   IRB#:11- 183 A  (2) 
73 
Amended: 20 -JAN -2016 
 High risk trials are monitored once per quarter, moderate risk twice per year and low risk 
once annually.  
  
16.7  Therapeutic Response Review  
The Therapeutic Response Review Committee (TRRC) is MSKCC’s independent 
response review committee which annually evaluates therapeutic responses for participants in IRB/PB approved clinical trials where therapeutic efficacy is a stated 
primary objective, typi[INVESTIGATOR_200936]. The process, done in an unbiased 
blinded fashion, ensures the data from the institution’s therapeutic trials clinical research 
program is verified and vetted. Studies monitored by [CONTACT_200997] -NIH, in -
house, industrial trials, and multi -center trials where MSKCC is the coor dinating center, 
which are not reviewed by [CONTACT_200998].  
 
MSKCC’s TRRC review will serve as the committee that may review and confirm 
responses of POETIC patients. The TRRC will possibly randomly select cases on an 
annual basis. If a patient is selected to be reviewed by [CONTACT_200999], the clinical site will be 
notified by [CONTACT_201000].  
 
17.[ADDRESS_239677] (HIPAA).  Each participating institution will have an appropriate 
assurance on file with the Office for Human Research Protection (OHRP), NIH.  The Data and Coordinating Center is responsible for assuring that each participating 
institution has an OHRP assurance and must maintain copi[INVESTIGATOR_200937]. The Data and Coordinating Center is responsible for assuring 
that IRB approval has been obtained at each participating site prior to the first patient 
registration from that site.  
 
The risks and benefits of participation in this s tudy will be reviewed with the patient 
and/or parent/legal guardian.  
 
Enrollment on this study is on a voluntary basis and every effort will be made to maintain 
privacy and confidentiality.  The patient's records will be confidential. Only authorized 
individuals or agencies may inspect the records.  No identifying information will be used 
in reports or publications resulting from this study.  
 
The following section is a Mandatory Section that pertains to MSKCC only : 
It is the responsibility of the Research S taff to ensure that protocol subjects received the 
Center’s Notice of Privacy Practices.  If the subject has not received one, MSK 
personnel must provide a Notice of Privacy Practices and obtain acknowledgment before 
the subject participates in the study.  
 
   IRB#:11- 183 A  (2) 
74 
Amended: 20 -JAN -2016 
  
MSKCC’s Privacy Office may allow the use and disclosure of protected health 
information pursuant to a completed and signed Research Authorization form.  The use 
and disclosure of protected health information will be limited to the individuals described 
in the Research Authorization form.  A Research Authorization form must be completed 
by [CONTACT_079] [INVESTIGATOR_30505].  
 
REFERENCES/BIBLIOGRAPHY  
1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl 
Cancer Inst. 1990; 82: 4- 6. (a)  
 
2. Mainou- Fowler T, Angus B, Miller S, Proctor SJ, Taylor P, Wood KM. Micro- vessel 
density and the expression of vascular endothelial growth factor (VEGF) and platelet -
derived endothelial cell growth factor (PdEGF) in classical Hodgkin Lymphoma.  
Leukemia 2006; 47:223- 230.  
 
 3. Poon RT, Fan ST, and Won g J. Clinical implications of  circulating angiogenic factors 
in cancer patients. J C lin Oncol 2001:19:1207- 1225.  
  4. Senger DR, Perruzzi CA, Feder J, and Dvorak HF.  A highly conserved vascular 
permeability factor secreted by a variety of human and rodent tumor cell lines.  Cancer Res 1986;46: [ADDRESS_239678], Galli SJ, Dvorak AM, Pemuzzi CA, Harvey VS, and Dvorak HF. Tumor cells secrete a vascular permeability  factor that promotes accumulation of ascites fluid.   
Science 1983;219:983- 985.  
 
6. Folkman J. Fundamental concepts of the process of angiogenesis.  Current Mol Med 
2003;3:643 -651.  
 
7. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N.  Vascular endothelial 
growth factor is a secreted angiogenic mit ogen.  Science1989; 246: [ADDRESS_239679], Zacharoulis S , Bramley AH , Vincent L, Costa C , MacDonald 
DD, Jin DK , Shido K , Kerns SA , Zhu Z , Hicklin D, Wu Y , Port JL , Altorki N, Port ER , 
Ruggero D , Shmelkov SV , Jensen KK , Rafii S , Lyden D . VEGFR1 -positive 
haematopoietic bone marrow progenitors initiate t he pre- metastatic niche. Nature 2005; 
438:820- 927.  
 
9. Kaya M, Wada T, Akastsuka T et al. Vascular endothelial growth factor expression in 
untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res. 2000; 6:572 -577.  
 10. Langer,I.  et al.  Expression of vascular endothelial growth factor (VEGF) and VEGF 
receptors in human neuroblastomas. Med Pediatr Oncol. 2000; 34: 386 -393.  
 
 
   IRB#:11- 183 A  (2) 
75 
Amended: 20 -JAN -2016 
 11.  Salven P, Orpana A, Teerenhori L, Joensuu H.  Simultaneous elevation in the 
serum concentrations of the angiogenic growth factors VEGF and bFGF is an 
independent predictor of poor prognosis in non- Hodgkin lymphoma: a single- instituti on 
study of 200 patients.  Blood 2000; 96: 3712- 3718.   
 
12.  Arush MW, Barak AB, Maurice S, Livne E.  Serum VEGF as a significant marker of treatment response in Hodgkin Lymphoma. Ped Hematol Oncol 2007; 24:111- 115.  
 13. Kieran M Anti -angiogenic therapy in pediatric neuro- oncology . J Neurooncol. 2005; 
75:327- 34.  
 14. Hurwitz,H.  et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for 
metast atic colorectal cancer. N  Engl J  Med 2004; 350:2335 -2342.  
 
15. Rowe,D.H.  et al.  Suppression of primary tumor growth in a mouse model of human 
neuroblastoma. J  Pediatr  Surg  2000;35:977- 981. 
 
16. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome 
and bevacizumab [letter]. N Engl J Med 2006;  354:981– 2. 
17. Glusk er P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome 
and bevacizumab [lette r]. New Engl J Med 2006;354:980- 1. 
18. Hambleton J, Skillings JR, Kabbinavar F, et al. Safety of low -dose aspi[INVESTIGATOR_248] (ASA) in a 
pooled analysis of 3 randomized, controlled trials (RCTs) of bevacizumab (BV) with 
chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin 
Oncol 2005;[ADDRESS_239680] 16S:3554.  
19. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg 
Oncol 2005;91:173– 80. 
20. Sandler A, Gray R, Perry MC, et al. Paclitaxel -carboplatin alone or with bevacizumab 
for non- small -cell lung cancer. New Engl J Med 2006;355(24):2542– 50. 
21. Miller KD, Chap LI, Holmes FA, et  al. Randomized Phase III trial of capecitabine 
compared with bevacizumab plus capecitabine in patients with previously treated 
metastatic breast cancer. J  Clin Oncol 2005;  23:792– 9. 
22.  Karp JE, Gojo I, Pi[INVESTIGATOR_45769] R, Gocke CD, Greer J, Guo C, Qian D, Morris L, Tidwell M, 
Chen H, and Zweibel J. Targeting vascular endothelial growth factor for relapsed and 
refractory adult acute myelogenous leukemias: therapy with sequential 1- beta- d-
arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clin Cancer Res . 2004; 
10(11):   3577- 85.  
23. Wedam SB, Low JA, Yang X, et al. A pi[INVESTIGATOR_200938]. J  Clin Oncol 2004;  [ADDRESS_239681] 14S:578.  
   IRB#:11- 183 A  (2) 
76 
Amended: 20 -JAN -2016 
 24. D’Adamo DR, Anderson S, Albritton K, et al. Cardiac toxicity in a phase II study of 
doxorubicin and bevacizumab for patients with metastatic soft -tissue sarcomas. J Clin 
Oncol 2004;[ADDRESS_239682] 14S:9012.  
25. Kretschmar C S, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, 
London WB, and Castleberry R. Response to paclitaxel, topotecan, and topotecan-
cyclophosphamide in children with untreated disseminated neuroblastoma treated in an 
upfront phase II investigati onal window: a pediatric oncology group study. J Clin Oncol. 
[ADDRESS_239683] 15;22(20):4119 -26.  
 
26. Allen JC and Helson L. High- dose cyclophosphamide chemotherapy for recurrent 
CNS tumors in children. J Neurosurg 1981; 55(5):749- 56. 
 
27. Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront 
window of pharmacokinetically guided topotecan in high- risk medulloblastoma and 
supratentorial primitive neuroectodermal tumor. J Clin Oncol 2004; 22(16):3357- 365. 
 
28. Kadota RP, Stewart CF, Horn M, et  al. Topotecan for the treatment of recurrent or 
progressive central nervous system tumors - a pediatric oncology group phase II study.  
J Neurooncol 1999; 43(1):43 -47. 
 
29. Frangoul H, Ames MM, Mosher RB, et al. Phase I study of topotecan administered 
as a 21-day continous infusion in children with recurrent solid tumors: a report from the 
Children's Cancer Group. Clin Cancer Res 1999; 5(12):3956- 3962.  
 30. Willett CG , Boucher Y , Duda DG , di Tomaso E , Munn LL, Tong RT , Kozin SV , Petit 
L, Jain RK , Chung DC, Sahani DV , Kalva SP, Cohen KS , Scadden DT, Fischman AJ , 
Clark JW , Ryan DP , Zhu AX , Blaszkowsky LS , Shellito PC, Mino -Kenudson M , Lauwers 
GY. Surrogate markers for antiang iogenic therapy and dose- limiting toxicities for 
bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. Journal of Clinical Oncology 2005; 23: 8136- 8139.  
 31. Tong RT, Boucher Y , Kozin SV, Winkler F , Hicklin DJ , Jain RK . Vascular 
normalization by [CONTACT_200945] 2 blockade induces a 
pressure gradient across the vasculature and improves drug penetration in tumors. 
Cancer Research 2004; 64:3731- 6. 
 32. Winkler F , Kozin SV, Tong RT , Chae SS , Booth MF, Garkavtsev I , Xu L , Hicklin DJ , 
Fukumura D , di Tomaso E , Munn LL, Jain RK . Kinetics of vascular normalization by 
[CONTACT_200969]2 blockade governs brain tumor response to radiation: role of oxygenation, 
angiopoietin- 1, and matrix metalloproteinases. Cancer Cel l 2004; 6: [ADDRESS_239684] of vascular normalization by [CONTACT_201001], peritumor edema and lymphatic metastasis: insights 
from a mathematical model. Cancer Res. 2007;  67:2729- 35. 
 
34. Dickson  PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL  
et al. Bevacizumab- induced transient remodeling of the vasculature in neuroblastoma 
xenografts results in improved delivery and efficacy of systemically administered 
chemotherapy. Clin C ancer Res 2007; 13(13):3942- 3950.  
   IRB#:11- 183 A  (2) 
77 
Amended: 20 -JAN -2016 
  
35. Arush MW, Barak AB, Maurice S, Livne E.  Serum VEGF as a significant marker of 
treatment response in Hodgkin Lymphoma. Ped Hematol Oncol 2007; 24:111- 115.  
 
36. Condoleelis, J, Pollard JW. Macrophages: obligate partners for tumor cell migration, 
invasion, and metastasis. Cell. 2006;124:263 -6. 
 
37. Okamoto R, Ueno M, Yamada Y, Takahashi N, Sano H, Suda T, Takakura N. 
Hematopoietic cells regulate the angiogenic switch during tumorigenesis.  Blood. 2005; 
105: [ADDRESS_239685] cancer. 
Cancer Research 2006; 66:[ZIP_CODE]- 46. 
 39. Ruan J , Hyjek E , Kermani P , Christos PJ , Hooper AT, Coleman M , Hempstead B , 
Leonard JP , Chadburn A , Rafii S . Magnitude of stromal hemangiogenesis correlates with 
histologic subtype of non- Hodgkin's lymphoma. Clinical Cancer Research.  2006; 12: 
5622- 31. 
 40. Kaplan RN , Riba RD, Zacharoulis S , Bramley AH , Vincent L, Costa C , MacDonald 
DD, Jin DK , Shido K , Kerns SA , Zhu Z , Hicklin D, Wu Y , Port JL , Altorki N, Port ER , 
Ruggero D , Shmelkov SV , Jensen KK , Rafii S , Lyden D . VEGFR1 -positive 
haematopoietic bone marrow progenitors initiate the pre- metastatic niche. Nature. 2005; 
438:820- 927. 
 
41.  Dome B, Timar J, Dobos J, Meszaros L, Raso, E, Paku S, Kenessey I, Ostoros G, 
Magyar M, Landanyi A, Bogos and Tovari J.  Identification and Clinical Significance of Circulating Enothelial Progenitor Cells in Human Non- Small Cell Lung Cancer.  Cancer 
Research. 2006; 66:7341- 7347.  
 
42. Fürstenberger G , von Moos R , Lucas R , Thürlimann B , Senn HJ , Hamacher J
, 
Boneberg EM .  Circulating endothelial cells and angiogenic serum fac tors during 
neoadjuvant chemotherapy of primary breast cancer. British Journal of Cancer. 2006; 
94:524- 31. 
 
43. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. 
Increased levels of viable circulating endothelial cells Annals of Oncol ogy. 2004;15:139-
145. 
 44. Lin EH, Hassan M, Li Y, Zhao H, Nooka A, Sorenson E, Xie K, Champlin R Wu, X, Li 
D.   Elevated circulating endothelial progenitor marker CD133 messenger RNA levels 
predict colon cancer recurrence.  
 
45. Igreja C , Courinha M , Cachaço AS , Pereira T , Cabeçadas J , da Silva MG , Dias S . 
Characterization and clinical relevance of circulating and biopsy -derived endothelial 
progenitor cells in lymphoma patients. Haematologica 2007;92:469- 477. 
 
 
   IRB#:11- 183 A  (2) 
78 
Amended: 20 -JAN -2016 
 46. Kosaka Y, Mimori K, Fukagawa T, Ishikawa K, Etoh T, Katai H, Sano T, Watanabe, 
M, Sasako, Mori M. Identification of the high -risk group for metastasis of gastric cancer 
cases by [CONTACT_201002] r receptor -1 overexpression in peripheral 
blood. British Journal of Cancer 2007; 96:1723- 1728.  
 47. Drev s J, Zirrgiebel U, Schmidt -Gersbach CI, Mross K, Medinger M, Lee L, Pi[INVESTIGATOR_17872] 
J, Wood J, Thomas AL, Unger C, Henry A, Steward WP, Laurent D, Lebwohl D, Dugan 
M, Marme D.  Soluble markers for the assessment of biological activity with PTK787/ZK 
222584 (PTK/ZK ), a vascular endothelial growth factor receptor (VEGFR) tyrosine 
kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann 
Oncol. 2005; 16(4):558 -65. 
 
48. Shaked Y, Bocci G, Munoz R, Man S, Ebos JM, Hicklin DJ, Bertolini F, D'Amato R, 
Kerbel RS.  Cellular and molecular surrogate markers to monitor targeted and non -
targeted ant iangiogenic drug activity and determine optimal biologic dose. Curr Cancer 
Drug Targets. 2005; 5(7):551- 9. 
 
49. Aref S, El Sherbiny M, Goda T, Fouda M, Al Askalany H, Abdalla D.  Soluble 
VEGF/sFLt1 ratio is an independent predictor of AML patient out come. Hematology 
2005; 10(2):131- 4. 
 50. Klisch J, Kubalek R, Scheufler KM, Zirrgiebel U, Drevs J, Schumacher M.  Plasma 
vascular endothelial growth factor and serum soluble angiopoietin receptor sTIE -2 in 
patients with dural arteriovenous fistulas: a pi[INVESTIGATOR_799]. Neuroradiology 2005; 47(1):10- 7. 
 
51. Reusch P, Barleon B, Weindel K, Martiny -Baron G, Godde A, Siemeister G, Marme 
D. Identification of a soluble form of the angiopoietin receptor TIE -2 released from 
endothelial cells and present in human blood. Angiogenesis. 2001; 4(2):123- 31. 
 52. Taylor AP, Osorio L, Craig R, Raleigh JA, Ying Z, Goldenberg DM, Blumenthal 
RD.Tumor -specific regulation of angiogenic growth factors and their receptors during 
recovery from cytotoxic therapy. Clin Cancer Res. 2002; 8(4):1213- 22. 
 
53. Cunning ham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab 
plus irinotecan in irinotecan- refractory metastatic colorectal cancer. N Engl J Med. 
2004;351:337 -345. 
 
54. Kurhanewicz J, Vigneron DB, Nelson SJ, al. e. Citrate as an in vivo marker to 
discriminate prostate cancer from benign prostatic hyperplasia and normal prostate 
peripheral zone:  detection via localized proton spectroscopy. Urology. 1995;45:[ADDRESS_239686] lesions 
distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology. 
1997;204:661 -666. 
 
56. Biomarkers Definition Working Group N. Biomarkers and surrogate endpoints: 
 preferred definitions and conceptual framework. Clinical Pharmacol Ther. 2001: 89-95. 
 
57. Schmidt C. Metabolomics takes its place as latest up- and-coming  "omic" science. 
Journal of the  National Cancer Institute. 2004;96:732- 734. 
   IRB#:11- 183 A  (2) 
79 
Amended: 20 -JAN -2016 
  
58. Evelhoch JL, Gillies TJ, Karczmar GS, al. e. Applications of magnetic resonance in 
model systems:  Cancer therapeutics. Neoplasia. 2000;2:152 -165. 
 
59. Griffiths JR, al. e. Metabolic changes detected by [CONTACT_201003]- 1 wild -type tumor deficient in hypoxia- inducible factor 1 -beta (HIF- 1beta): 
 evidence of an anabolic role fo r the HIF-[ADDRESS_239687]. Cancer Research. 2002;62:[ADDRESS_239688] cancer cells treated with anti -mitotic drugs:  a 31P -magnetic 
resonance spectroscopy study. Cancer Research. 2001;61:7536- 7542.  
 
61. Gottschalk S, Anderson N, Hainz C, Eckhardt SG, Serkova NJ. Imatinib (STI571) -
mediated changes in glucose metabolism in human leukemia BCR -ABL positive cells. 
Clinical Cancer Research. 2004;10:6661 -6668.  
 
62. Ackerstaff E, G lunde K, Bhujwalla ZM. Choline phospholipid metabolism:  A target in 
cancer cells  ? J Cell Biol. 2003;90:525- 533. 
 
63. Baguley BC, Marshall ES. In vitro modelling of human tumour behaviour in drug 
discovery programmes. Eur J Cancer. 2004;40:794- 801. 
 64. Agrawal S, Temsamani J, Tang JY. Pharmacokinetics, biodistribution, and stability of 
oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci U S A. 
1991;88:7595 -7599.  
 65. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations.  J Am 
Stat Assoc. 1958;53:457 -480. 
 66. Serkova N, Fuller TF, Klawitter J, Freise CE, Niemann CU. 1H -NMR -based 
metabolic signatures of mild and severe ischemia/re -perfusion injury in rat kidney 
transplants. Kidney Int. 2005;67:1142 -1151.  
 
67. Smith A, Hennessy J, Heisel Kurth M, and Nelson S. Reversible skeletal changes 
after treatment with bevacizumab in a child with cutaneovisceral angiomat osis with 
thromb ocytopenic syndrome. Pediatr Blood Cancer2008; 51(3): 418- 420. 
 
68.Glade- Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel 
RS,,Cooney -Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, 
Blaney SM, Kandel JJ, Yamashiro DJ. Phase I trial and pharmacokinetic study of 
bevacizumab in pediatric patients with refractory solid tumors:  A Children’s Oncology 
Group Study. J Clin Oncol 2008, 26(3): 399 -405. 
 
69. Saylors RL, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, Harris MB, 
Hayashi R, Vietti TJ. Cyclophosphamide plus topotecan in children with recurrent or 
refractory solid tumor: A Pediatric Oncology Phase II Study. J Clin Oncol 2001, 19:3463-
3469.  
 
   IRB#:11- 183 A  (2) 
80 
Amended: 20 -JAN -2016 
 70. Griffin, JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer. 2004 
Jul:4(7):551- 61. 
 71. Figure provided by [INVESTIGATOR_124]. David Lyden on page 76 of the Appendix (Figure 1). 
 
 
 
 
 
Figure 1.  
 
 
 
 
  
Figure 1: Periph eral rim of t umor with blue Dapi [INVESTIGATOR_200939] -derived and localize to 
the invasive front of the tumor .   
   IRB#:11- 183 A  (2) 
81 
Amended: [ADDRESS_239689] Cancer Patient  mononuclear cells stained for CD45, CD34 and VEGFR1  

   IRB#:11- 183 A  (2) 
82 
Amended: 20 -JAN -2016 
 Table 3  
 
 
Table3: Levels of CD34+/VEGFR1- HSC/HPCs, CD34+/VEGFR1+ HPCs, and CD34-
/VEGFR1+ macrophages were measured in Normal Controls (n=6), patients with a new 
diagnosis of rhabdomyosarcoma (n=4) and in remission (n=6).  Patients with new diagnosis had the highest HPCs and there was a r eduction in these levels in patients 
who were with no evidence of disease after completion of therapy.  
  Normal 
Controls 
(n=6)  Std. 
Dev.  New 
Diagnosis 
(n=4)  Std. 
Dev.  Remission 
(n=6)  Std. 
Dev.  
CD34+/VEGFR1- HSC/HPCs  0.41 0.33  0.46 0.37 0.368  0.368  
CD34+/VEGFR1+ HPCs  1.205  0.713   2.77 0.869  0.79 0.824  
CD34-/VEGFR1+ Mature 
monocytes  19.191  6.182   20.446  7.992  42.6 17.865  
CD133+/VEGFR2+ EPCs  0.28 0.14  0.83 0.45 0.46 0.38 